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C hronic illnesses form a spectrum of diseases. some chronic illnesses are poorly understood and unpredictable, some are understood and manageable, some 
are progressively disabling and some are life threatening. nevertheless, for all 
chronic patients chronic illnesses have one thing in common: the patient will never 
again return to the pre-illness state of invulnerability of obliviousness to the body’s 
functioning. in chronic patients, symptoms may interfere to varying degrees with the 
ability to work, to carry out family and social roles and to rest 1. it is in this light that 
a measure like Health Related Quality of life (HRQol) can be of great use. 
HRQol is a psychosocial outcome that reflects a person’s health and how a 
disturbance of a person’s health influences his or her functioning in daily life 2. 
HRQol provides information about the physical, social and mental burden of 
disease and is complementary to the clinical, biochemical and physiologic outcomes, 
which provide information about the pathological course of the disease 3. although 
clinicians may be more concerned about the traditional biological outcomes, patients 
are more concerned about the impact of disease and related treatments on quality of 
life 4.
Chronic liver disease is associated with significant morbidity and mortality. 
Patients may suffer from complications of cirrhosis like ascites, variceal bleedings and 
hepatic encephalopathy, which are easily evaluated by traditional clinical measures. 
yet, many chronic liver patients are put up with non-specific symptoms like fatigue, 
abdominal discomfort, nausea and depression. these symptoms are hard to evaluate, 
however 5,6. therefore, in clinical practice the severity of these symptoms may get less 
attention than required, although these symptoms may have a significant impact on 
HRQol. 
in the past decades, research by means of generic and liver disease-specific 
HRQol questionnaires has increased our insight in the HRQol of chronic liver 
patients. Many of these studies compared the HRQol between pre-transplanted 
and post-transplanted liver patients or focused on the impact of a certain therapy, 
such as interferon therapy on HRQol 7-10. others compared the HRQol of patients 
with various disease stages or aetiologies or were directed to the HRQol impact of a 
specific aetiology like hepatitis C or cholestatic diseases 11-14. However, the majority 
of these studies were conducted in relatively small clinical populations or restricted 
to a certain disease stage or aetiology, leaving limited space for correction for other 
potentially disturbing factors of HRQol. furthermore, the used liver disease-specific 
questionnaires were predominantly directed to measurement of symptom severity, 
but disregarded the measurement of experienced hindrance of symptoms during 
daily activities 15-18.
the research on HRQol of chronic liver patients described in this thesis was 
conducted in collaboration with the dutch liver patient association (nederlandse 
leverpatiënten vereniging (nlv)). in contrast to earlier studies, our investigation 
approached a population-based study since our large population of nlv members 
merely represented a general population of chronic liver patients. Moreover, the 
population-size and the amount variation in the population regarding aetiology and 
disease stage permitted extensive adjustment for potential confounders. this enabled 
us to evaluate the impact of disease stage and aetiology on the HRQol (generic 
HRQol, disease-specific HRQol and fatigue) of chronic liver patients. 
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Before we started the analyses we aimed for, we validated the construct validity of 
the liver disease symptom index 2.0, a disease-specific questionnaire developed at 
our department of gastroenterology and Hepatology at the erasmus Medical Center 
Rotterdam (chapter 2). 
our main aim was to evaluate the impact of disease stage (non-cirrhosis, 
compensated cirrhosis and decompensated cirrhosis) and liver transplantation 
(chapter 3), aetiology (viral hepatitis, autoimmune hepatitis, cholestatic diseases, 
hemochromatosis and other liver diseases) (chapter 4) and more specifically the 
impact of viral hepatitis B and C (chapter 5) on the HRQol of chronic liver patients. 
finally, we integrated the findings described in former chapters, to put the HRQol 
of specific liver patient subgroups in perspective with the HRQol of other liver 
patients, non-liver patients and healthy controls (chapter 6).
Chapter 1
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aBstRaCt
Background: the available liver disease-specific questionnaires do address severity 
of symptoms but hardly evaluate how patients experience these specific symptoms 
during daily activities. the liver disease symptom index 2.0 (ldsi) includes 18 
items that measure symptom severity and symptom hindrance in the past week. 
Methods: in a large survey (n=1175) conducted in collaboration with the dutch liver 
patient association, we evaluated the convergent and divergent construct validity 
of the ldsi with the sf-36 and the Mfi-20 and the surplus value of including both 
symptom severity and symptom hindrance items in the ldsi. 
Results: the ldsi items showed expected convergent and divergent correlations 
with short form-36 (sf-36) and Multidimensional fatigue index-20 (Mfi-20) scales. 
Correlations revealed only a slight to moderate overlap between ldsi items and 
sf-36 and Mfi-20 scales. with respect to the surplus value of the symptom severity 
and symptom hindrance items, we found that the impact of symptom hindrance on 
generic HRQol varied in a different way across different levels of generic HRQol 
than symptom severity. this indicated that symptom severity items and symptom 
hindrance items measured different aspects of HRQol.
Conclusions: we conclude that the ldsi provides information complementary to the 
information given by the sf-36 and the Mfi-20 and that it is psychometrically sound 
to include both symptom severity items and symptom hindrance items in the ldsi.
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Chapter 2
i n the past decades, most research on HRQol of chronic liver patients focused on treatment induced change in HRQol, the variation of HRQol across disease 
stages and the comparison of HRQol between aetiologies. for these purposes, 
a liver disease-specific questionnaire has been recommended 1. However, many 
studies investigated the HRQol of chronic liver patients by means of a generic 
questionnaire 2-5. turning point has been the development of the Hepatitis Quality 
of life Questionnaire. this questionnaire includes eight generic and two disease-
specific scales, which measure limitations in physical, role- and social activities and 
distress due to hepatitis 6-8. severity of specific symptoms or hindrance of specific 
symptoms in daily functioning has not been addressed in this questionnaire. in 
contrast, the Chronic liver disease Questionnaire, the liver disease Quality of life 
Questionnaire and the liver transplantation database Quality of life questionnaire 
do address symptom severity but hardly evaluate how patients experience these 
specific symptoms during daily activities 6-8. still, information about the way liver 
patients experience their symptoms and how these symptoms affect their daily 
activities could be important for individual disease management. in clinical practice, 
objective physiological and clinical outcomes do not always match the patient’s 
health perceptions 9-11. as a consequence, hepatologists may experience difficulties 
in understanding their patients. therefore, a disease-specific questionnaire that 
measures the experienced severity and hindrance of specific symptoms may provide 
important additional information. for this reason, we developed the liver disease 
symptom index (ldsi).
in an earlier study we evaluated the psychometric properties of the ldsi 12. 
several adjustments have followed from the first psychometric evaluation, which led 
to the ldsi 2.0. a pilot study, conducted in a clinical population pointed out that the 
ldsi 2.0 had an adequate feasibility and test-retest reliability, which allowed us to 
take the next step in the validation process: to evaluate the construct validity of the 
liver disease symptom index 2.0.
MetHods
the liver disease symptom index 2.0 (appendix 1)
the psychometric properties of the first ldsi version have been evaluated in a 
clinical population of chronic liver patients. Results were promising with respect 
to the feasibility, reliability and the discrimination between compensated cirrhotic 
and decompensated cirrhotic patients. However, difficulties arose with respect to the 
discrimination between compensated cirrhotic and non-cirrhotic patients. therefore, 
we changed the response categories to a five-point scale. we gave the ldsi a more 
multidimensional character by adding items on depression and worry about the 
family situation. since we intended to use the ldsi in a large survey on the HRQol 
of chronic liver patients organised in collaboration with the dutch liver patient 
association (nederlandse leverpatiënten vereniging (nlv), we consulted the board 
of the nlv for important disease-specific items still lacking in the ldsi. the nlv 
board included various chronic liver patients who, based on their experience and 
contact with other liver patients stressed the importance of itch as a cause of sleep 
validation of the liver disease symptom index 2.0
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deprivation and the hindrance of jaundice in social contacts. especially the item on 
itch was supported by the literature 13,14. However, we decided to include both items 
into the ldsi to improve our insight in the impact of these two symptoms.
the ldsi version 2.0 includes 18 items. nine items measured severity of: ‘itch’, 
‘Joint pain’, ‘Pain in the right upper abdomen’, ‘sleepiness during the day’, ‘worry 
about family situation’, ‘decreased appetite’, ‘depression’, ‘fear of complications’ 
and ‘Jaundice’. nine other items measure the hindrance of these symptoms to daily 
activities. the item ‘fear of complications’ has no accompanying hindrance item. the 
symptom ‘itch’ has two accompanying hindrance items (hindrance of itch during the 
day and during sleep). all items have ‘the last week’ as time frame and are scored on 
a 5-point scale ranging from ‘not at all’ to ‘to a high extent’. the single items have not 
been combined into multi-item scales, as we are of the opinion that in clinical practice 
results of separate symptom severity and symptom hindrance items are easier to 
interpret and more valuable for patient management.
extra nlv items 
apart from the ldsi 2.0 six extra nlv items were developed, which in the experience 
of the board of the nlv were important aspects of the HRQol of chronic liver patients 
(appendix 2). the items concern: ‘Memory problems’, ‘Change of personality’, 
‘Hindrance in financial affairs’, ‘involuntary change in use of time’, ‘decreased sexual 
interest’ and ‘decreased sexual activity’. these items are scored on a 5-point scale 
ranging from ‘not at all’ to ‘to a high extent’.
Background questionnaire
a background questionnaire was used to determine gender, age, education level, 
marital status, aetiology, duration of the liver disease, status of the liver disease(s) 
(cured, non-cured), liver transplant history, presence of cirrhosis, presence or history 
of splenomegaly, ascites or oesophageal variceal bleedings, presence of oesophageal 
variceal bleedings or ascites in the year 2000, history of complications of cirrhosis 
(liver cancer or imminent coma), comorbidity (defined as diseases or disorder other 
than the liver disease that limit the respondent’s daily activities), medication use 
and the amount of hours per week spent on work and activities with and without 
physical effort.
other questionnaires
for the validation of the construct validity of the ldsi and the extra nlv items, we 
used the short form-36 (sf-36) and the Multidimensional fatigue index-20 (Mfi-20) 
15,16. Both questionnaires proved to be reliable and valid instruments in a chronic liver 
patient population 12. the sf-36 includes 8 scales: Physical functioning, Role limitations 
due to Physical problems, Bodily Pain, general Health, vitality, social functioning, Role 
limitations due to emotional problems and Mental Health. the scale scores range from 
0 to 100. a higher score indicates a better generic HRQol. the domain-specific Mfi-20 
measures 5 types of fatigue: general fatigue, Physical fatigue, Reduction in activity, 
Reduction in Motivation and Mental fatigue. scale scores range from 4 to 20. a higher 
score indicates more fatigue. the Mfi-20 questionnaire was used because fatigue is an 
important complaint of chronic liver patients 17,18.
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Pilot-testing of the ldsi 2.0
Preparatory to a large survey on HRQol of chronic liver patients in the netherlands 
in collaboration with the nlv, we tested the feasibility and test-retest reliability of 
the ldsi 2.0 and the background questionnaire in a pilot study at the outpatient 
clinic of our Hepatology department at the erasmus Medical Center Rotterdam, 
the netherlands. during routine visits, hundred consecutive chronic liver patients 
received two copies (a test and a retest questionnaire) of the ldsi and the background 
questionnaire. Patients were asked to complete the questionnaires at home with an 
interval of three days. all respondents signed an informed consent form. in total 34 
respondents completed the questionnaires in three days. sixty-nine respondents 
returned the test and the retest questionnaire (mean time-interval 4.4 days, sd 2.9). 
six patients returned just one questionnaire, while 25 patients did not respond.
we evaluated the test-retest reliability of the ldsi and the extra nlv items by 
means of weighed kappas in respondents with a test-retest interval of three days 
(n=34). we chose this short interval to decrease the potential variation in symptom 
severity so that a potential low agreement between the test and the retest could 
be predominantly attributed to change of item interpretation. kappas < 0.20 were 
defined as ‘poor’, 0.21-0.40 as ‘fair’, 0.41-0.60 as ‘moderate’, 0.61-0.80 as ‘good’ and 
0.81-1.00 as ‘very good’ 19. thirteen ldsi items showed a good to very good test-retest 
reliability (κweighed 0.63 to 0.99). three items (severity and hindrance of depression and 
hindrance of decreased appetite) showed a moderate test-retest reliability (κweighed 
0.55 to 0.57). one item (hindrance of worry about the family situation) showed a fair 
test-retest reliability (κweighed 0.32). of the extra nlv items 5 showed a good test-retest 
reliability (κweighed 0.66 to 0.82), while the item on memory problems showed a very 
good test-retest reliability (κweighed 0.91).
we evaluated the feasibility of the ldsi and extra nlv items in the 69 respondents 
who returned test and retest questionnaires. items with 5% missing values or less 
were defined as having a good feasibility. we defined items as missing if no answer 
was provided or if multiple responses were given when only one was required. the 
ldsi items in both the test and retest questionnaires showed a good feasibility. in the 
test questionnaire the extra nlv items on financial affairs and sexuality demonstrated 
a slightly decreased feasibility of 5.8%. 
in the same 69 respondents, we evaluated the reliability of respondent-reported 
clinical symptoms (presence of cirrhosis and presence or history of splenomegaly, 
ascites and oesophageal variceal bleedings) and respondent-reported aetiology in the 
background questionnaire. we used kappas to evaluate the agreement between test- and 
retest questionnaires and the agreement between reported data and data in the hospital 
file. furthermore, we used kappas to evaluate the disease stage definitions that were 
based on reported clinical symptoms. we defined respondents without any of the clinical 
symptoms as non-cirrhotic. Respondents who reported cirrhosis and/or a history of 
splenomegaly and/or ascites were defined as compensated cirrhotic. Respondents with 
oesophageal variceal bleedings were defined as decompensated cirrhotic. 
the items concerning presence of cirrhosis and presence or history of splenomegaly, 
ascites and oesophageal variceal bleedings, showed very good test-retest reliabilities 
(κ 0.85 to 0.97). Reported splenomegaly, ascites and oesophageal variceal bleedings 
showed a good agreement with hospital data with kappas of respectively 0.71, 
0.71 and 0.68. a moderate agreement was shown between reported cirrhosis and 
validation of the liver disease symptom index 2.0
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the hospital data (κ 0.52) as respondent’s misunderstood cirrhosis for fibrosis. the 
reported aetiologies showed a good agreement between the test questionnaire and 
the retest questionnaire (κ 0.71) and a good agreement with the hospital data (κ 0.63). 
the assigned disease stages based on our disease stage definitions showed only 
a fair agreement with the disease stages based on hospital data of the patients (κ 
0.37). the hospital data revealed that our disease stage definitions disregarded the 
temporary state of the decompensated cirrhotic stage. with the current treatment 
modalities (diuretics or surgical interventions) decompensated cirrhotic patients 
often reverse to an apparently compensated state. during the survey in the nlv 
population, we took this temporary state of decompensated cirrhosis into account 
by including the item concerning: the presence of ascites or oesophageal variceal 
bleedings in the year 2000 (the year of the study) into the background questionnaire. 
this extra criterion distinguished recent decompensated cirrhotic patients from 
reversed decompensated cirrhotic patients. 
validation of liver disease symptom index 2.0 and nlv items
as the ldsi 2.0 showed an adequate feasibility and test-retest reliability, we used a 
large survey on HRQol of chronic liver patients in the netherlands to evaluate the 
convergent and divergent construct validity of ldsi and the extra nlv items and the 
surplus value of including symptom severity and symptom hindrance items in the 
ldsi 2.0. 
in october 2000, 2020 nlv members received a questionnaire by mail. the 
questionnaire included the ldsi, the extra nlv items, the sf-36, the Mfi-20 and the 
background questionnaire. non-responders received a second mailing. we closed 
the response period 5 months after the first mailing. Respondents completed the 
questionnaire anonymously and gave their informed consent by confirming their 
willingness to participate in the first question of the background questionnaire.
statistical methods
we performed all analyses in sPss 10.0.
we used spearman correlations to evaluate convergent and divergent construct 
validity between ldsi’s symptom severity and symptom hindrance items. we 
expected that a specific symptom severity item and its accompanying symptom 
hindrance item would show stronger convergent relations than other symptom 
severity and symptom hindrance item combinations. for these calculations solely 
symptomatic respondents were selected, since we assumed that solely symptomatic 
patients have symptom hindrance. 
we also used spearman correlations to evaluate the convergent and divergent 
construct validity between ldsi items or extra nlv items and the sf-36 or the Mfi-
20 scales. By means of these correlations we evaluated if the ldsi items showed 
convergent and divergent relations with the expected scales and if the ldsi offered 
HRQol information additional to the information provided by the sf-36 or Mfi-20. 
spearman correlations < 0.4 were regarded as low, 0.4 to 0.7 as moderate, ≥ 0.7 as high 19. 
significance level was p < 0.0002 to correct for multiple comparisons.
to investigate the surplus value of including symptom severity as well as 
symptom hindrance items in the ldsi, we evaluated if symptom severity items and 
22
Chapter 2
symptom hindrance items differed with respect to their impact on generic HRQol. if 
the impact (odds ratio) differed between symptom severity and symptom hindrance, 
this would indicate that symptom severity items measure another aspect of HRQol 
than symptom hindrance items. we expected that these impacts would change across 
different levels of generic HRQol. therefore, we divided the generic HRQol of 
liver patients in three levels, based on cut off values of generic HRQol in healthy 
controls. 
we assumed that the 10-25% healthy controls with the lowest generic HRQol 
scores could be considered as controls with a poor generic HRQol. Consequently, 
we considered liver patients with a generic HRQol score equal or lower than the 
HRQol score of the 25th percentile of the healthy controls, as liver patients with a 
poor generic HRQol. in healthy controls we calculated for each sf-36 scale, the 
score corresponding to the ≤10th, 11th-25th and >25th percentile. in liver patients we 
used these scores as cut off values for categorisation of their scale specific HRQol. 
thus, for every sf-36 scale, the score range was split up in group a: liver patients 
with scale scores corresponding to the ≤10th percentile of healthy controls; group B: 
liver patients with scale scores corresponding to the 11th-25th percentile of healthy 
controls; and group C (reference): liver patients with scale scores corresponding 
to the >25th percentile of healthy controls. for the analyses, we used multinomial 
regression, which allows outcomes with more than 2 categories. the three categories 
of generic HRQol (a, B and C) served as dependent outcome. group C served as the 
reference group. the symptom severity items or the symptom hindrance items were 
independent determinants. for every ldsi item we calculated two odds ratios: the 
odds ratio of a HRQol score in group a relatively to a score in group C and the odds 
ratio of a HRQol score in group B relatively to a score in group C. 
we conducted similar analyses to evaluate if symptom severity items and 
symptom hindrance items differed with respect to their impact on fatigue.
Results
Characteristics of the clinical liver patient population and the dutch liver patient population 
table 1 shows the characteristics of the clinical pilot population, the nlv population 
and the characteristics of the sf-36 and Mfi-20 healthy controls. 
in total 2020 nlv members received a questionnaire of which 1617 were returned. 
of these, 374 respondents were non-patient member who joined the nlv because of 
involvement with liver patients in family, circle of acquaintances or work. in total 
1243 had a (history of ) liver disease. of these, 1222 gave informed consent, but 47 were 
younger than 18 years of age. in total 1175 respondents were included in the analysis. 
assuming that the percentage of patient members is equal in non-responders and 
responders (76%), than the total number of patient members is 1553 and the response 
rate (n=1243) would be around 80%. 
the nlv population was significantly different from the clinical pilot population 
with respect to gender, disease stage and aetiology.
validation of the liver disease symptom index 2.0
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symptom severity and symptom hindrance frequencies
table 2 shows the frequency of symptomatic patients and the frequency of patients 
with symptom hindrance among the symptomatic patients. More than 50% of the 
patients experienced joint pain (58%), sleepiness (71%) during the day and worry 
about the family situation caused by the liver disease (51%). other symptoms were 
less common. of the liver patients experiencing symptoms, often more than 50% was 
hampered by the symptoms in daily activities. 
table 1: demographic and clinical characteristics of the clinical population, the nlv population and the sf-36 and Mfi-20 
controls.
asignificantly different between the clinical population and the nlv population p=0.011
bsignificantly different between the clinical population and the nlv population p=0.000 
csignificantly different between the clinical population and the nlv population p=0.000
 (when hemochromatosis and transplants excluded p > 0.05).  
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Construct validity
Construct validity is one of the most important characteristics of a measurement 
instrument. it assesses the degree to which an instrument measures what it was 
supposed to measure and relies upon expressing opinions about expected relations 
amongst constructs. Convergent relations anticipate correlations between a postulated 
HRQol item or dimension and all other dimensions that theory suggests should be 
related to it. divergent relationships anticipate that some items or dimensions of 
HRQol are relatively unrelated. additionally, these correlations indicate if items 
are redundant because they overlap or duplicate the information contained in other 
items 19. 
table 3 shows the spearman correlations between specific symptom severity 
items and their accompanying symptom hindrance item. as expected, symptom 
severity items showed stronger convergent relations with their accompanying 
symptom hindrance item than with other symptom hindrance items. Most of these 
item-pair correlations were of moderate strength. items regarding the severity of 
joint pain, sleepiness during the day and depression showed high correlations with 
their accompanying hindrance item, suggesting overlap between the information 
provided by these items.
table 4 and 5 show that all ldsi items are low to moderately correlated with 
the sf-36 and Mfi-20 scales, indicating a slight to moderate overlap between the 
information given by the ldsi and the other two questionnaires. as expected, 
‘(hindrance of ) joint pain’ showed convergent relations with particularly the physical 
scales of the sf-36. Joint pain hampers activities like bending, kneeling, walking and 
climbing stairs. items, which are specifically measured by the physical functioning 
scale. logically, these limitations hamper in daily activities and affect vitality, as 
table 2: frequencies of symptomatic respondents per ldsi or nlv item and within these groups the percentage respondents 
with symptom hindrance to daily activities in the nlv population (n=1175).
validation of the liver disease symptom index 2.0
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shown by the correlations between hindrance of joint pain and the role physical, 
vitality, general fatigue and physical fatigue scales. ‘(Hindrance of ) depression’ was 
expected to show convergent relations with multiple sf-36 scales, as depression, 
could affect the overall burden of patients with a chronic medical illness 20. similarly, 
‘(Hindrance of ) worry’ showed multiple convergent relations. ’(Hindrance of ) 
sleepiness showed expected convergent relations with most Mfi-20 scales and the 
sf-36 vitality scale that evaluates feelings like ‘being worn out’ and ‘feeling full of 
pep’, but also with the role physical and social functioning scale which measure 
interference of physical problems in daily and social activities. ‘(Hindrance of ) itch’, 
‘(Hindrance of ) decreased appetite’, and ‘(Hindrance of ) jaundice’ predominantly 
showed divergent relations as these symptoms are not measured in the sf-36 or Mfi-
20, although decreased appetite’ and ‘vitality’ were unexpectedly associated. 
the extra nlv-items all showed low to moderate correlations with ldsi items 
and the sf-36 and Mfi-20 scales. the item concerning memory problems showed 
convergent relations with mental fatigue, while ‘change of personality’ was associated 
with social functioning, which measures interference of emotional problems with 
social activities. the item concerning the ‘involuntary change in use of time due 
to the liver disease’, was moderately associated with ldsi’s worry, depression and 
sleepiness and almost all sf-36 and Mfi-20 scales, but not with the role emotional, 
mental health, reduction in motivation and mental fatigue scale. 
figure 1a and 1b respectively show the significant associations between symptom 
severity or symptom hindrance and poor generic HRQol. in these figures, poor 
HRQol of liver patients corresponds to the HRQol level of the 10% healthy controls 
with the lowest HRQol (group a). symptom hindrance was associated with larger 
odds ratios of poor generic HRQol than symptom severity. for instance, being 
hampered by joint pain demonstrated odds ratios of 9.43, 2.77, 12.51 and 2.89 for 
respectively a poor physical functioning, poor role physical functioning, severe 
bodily pain and a poor general health, while an increasing severity of joint pain 
demonstrated odds ratios of 2.53, 1.64, 5.17 and 1.87 on the same sf-36 scales. 
furthermore, hindrance of depression was associated with higher odds ratios of poor 
physical functioning (oR 2.90), poor general health (oR 2.10), poor social functioning 
(oR 8.13), poor role emotional functioning (oR 4.26) and poor mental health (8.72) 
than an increasing severity of depression (oR range: 1.57 in physical functioning 
to 4.00 in mental health). similar results were found with respect to hindrance of 
table 3: ldsi construct validity. spearman correlations between a specific symptom severity item and the accompanying 
symptom hindrance item in a selected nlv population of symptomatic patients (for n, see table 2).
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abdominal pain, hindrance of decreased appetite, hindrance of worry about the 
family situation and hindrance of sleepiness during the day. 
figure 1c and 1d respectively show the significant relations between symptom 
severity or symptom hindrance and a poor generic HRQol, which corresponds to the 
HRQol of healthy controls in the 10th to 25th percentile (group B). these figures show 
the same tendency as the former two. odds ratios of symptom severity and symptom 
hindrance for this HRQol level (B) were often significantly lower than the odds ratios 
for the poorer HRQol level (a). However, the impact of symptom severity on HRQol 
was still lower than the impact of symptom hindrance.
when we evaluated the impact of symptom severity items and symptom 
hindrance on various levels of fatigue, the same tendency as described was found 
(not shown).
validation of the liver disease symptom index 2.0
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a)not significant: itch, fear, jau 
 4
H02/F1a
figure 1a and 1b: the effect (oR) of increasing symptom severity (a) and presence of symptom hindrance (b) on poor 
generic HRQol. the level of poor generic HRQol of chronic liver patients, corresponds to the HRQol of the 10% healthy 
controls with the worst generic HRQol (10th percentile). for the legend of the ldsi items and the sf-36 scales, see table 4.
 5
H02/F1b 
b) not significant: hitch, hjau
 6
H02/F1c
figure 1c and 1d: the effect (oR) of increasing symptom severity (c) and presence of symptom hindrance (d) on poor 
generic HRQol. the level of poor generic HRQol of chronic liver patients corresponds to the level of generic HRQol of 
healthy controls in the 10th to 25th percentile. for the legend of the ldsi items and the sf-36 scales, see table 4.
c) not significant: itch, wor, fear, jau
 7
H02/F1d 
d) not significant: hitch, hdap
validation of the liver disease symptom index 2.0
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disCussion
the liver disease symptom index is a disease-specific questionnaire for chronic liver 
patients. as validation is an ongoing process, several adjustments have followed from 
the first psychometric evaluation of the ldsi, which led to the ldsi 2.0. a pilot study 
convinced us that the ldsi 2.0 had an adequate feasibility and test-retest reliability, 
which allowed further validation of this disease-specific questionnaire. 
in this study we aimed to evaluate the construct validity of the liver disease 
symptom index 2.0. the convergent and divergent relations between the ldsi 
and the sf-36 and Mfi-20 revealed that there is only a slight to moderate overlap 
between ldsi items and the sf-36 and Mfi-20 scales. therefore, the disease-specific 
information given by the ldsi can be regarded as complementary to the generic and 
domain specific HRQol information. the additional explanatory value of the ldsi 
can be illustrated by convergent relations between ‘joint pain’, ‘sleepiness’, ‘worry’ 
and ‘depression’ items and multiple sf-36 and Mfi-20 scales. these symptoms seem 
to play an important part in the HRQol of general chronic liver patient population, 
but the moderate correlations with the scales indicate that these symptoms are only 
partly measured by the sf-36 and the Mfi-20. therefore, the additional information 
provided by the ldsi may deepen our insight in the HRQol of chronic liver patients 
and may support individual liver disease management. 
worth mentioning is that the construct validity of the first ldsi version was 
evaluated in a clinical population of outpatients and hospitalised patients (33%). 
the ldsi then showed mainly convergent relations between sf-36/Mfi-20 scales 
and ‘abdominal pain’, ‘fear’ and ‘decreased appetite’, probably due to the more 
severe condition of hospitalised patients. apparently, these symptoms played a 
less important part in the current general population of chronic liver patients. this 
indicates that the construction of the ldsi is valid for both clinical and general 
populations of chronic liver patients.
a potential weakness of the ldsi 2.0 seemed to be the high correlations between 
the severity of ‘Joint pain’, ‘sleepiness during the day’ and ‘depression’ and their 
accompanying hindrance item. Because of the high correlations one would expect 
that the symptom severity item and the symptom hindrance item give similar 
information. However, our analysis with respect to the associations between ldsi 
items and poor generic HRQol or severe fatigue demonstrated that presence of 
symptom hindrance has a larger impact on poor generic HRQol or severe fatigue 
than increasing symptom severity. this indicates that the symptom severity items 
and symptom hindrance items do measure different aspects of HRQol. 
furthermore, we demonstrated that the impact of symptom severity and symptom 
hindrance varied across liver patients. the impact of symptom severity and symptom 
hindrance was often significantly higher in liver patients with the poorest generic 
HRQol and the most severe fatigue. Moreover, we found that when the generic 
HRQol was less poor or the fatigue less severe, the impact of symptom hindrance 
decreased stronger than the impact of symptom severity. nonetheless, both impacts 
were still significantly higher compared to the impact of symptom severity and 
hindrance in liver patients with a normal generic HRQol or normal fatigue. these 
findings point out that the impact of symptom severity varies in a different way 
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across liver patients than the impact of symptom hindrance. this supports the value 
of including symptom severity items as well as symptom hindrance items in the 
disease-specific questionnaire. 
a limitation of our validation process is that it was conducted in a general 
population of chronic liver patients. the nlv population significantly differed from 
the clinical pilot-population with respect to gender, disease stage and aetiology. 
therefore, extrapolation of our findings to other (clinical) chronic liver patient 
populations should be done with caution. 
Moreover, the nlv may attract liver patients with a low HRQol seeking social 
support, although the social support received from other members may influence 
their HRQol positively. in a post-hoc analysis, we found that the nlv population 
had a higher symptom hindrance prevalence than the clinical population. this is 
surprising, as the clinical pilot population included relatively more patients with 
a compensated and decompensated disease stage. the higher symptom hindrance 
prevalence may have influenced our results regarding the impact of symptom 
severity and symptom hindrance on HRQol and therefore may not be representative 
for a clinical population of chronic liver patients. when we checked the impact of 
symptom severity and symptom hindrance on HRQol in our clinical population, we 
found that symptom severity and symptom hindrance alternately showed the largest 
impact across the sf-36 scales. although these findings do not reflect the tendency 
found in the nlv population, it nevertheless indicates that symptom severity items 
and symptom hindrance items do measure different aspects of HRQol.
future studies are needed for further psychometric refinement of the ldsi. in another 
study we evaluated the known groups validity of the ldsi for disease stages groups 
21. summary scores of symptom severity and symptom hindrance could be developed 
in order to facilitate population comparisons. additionally, the responsiveness of the 
ldsi needs to be examined, since the establishment of minimal important changes will 
support a better understanding of the ldsi results in clinical practice.
we conclude that the liver disease symptom index 2.0 provides HRQol 
information complementary to the HRQol information given by the sf-36 and the 
Mfi-20. the impact of symptom severity and symptom hindrance on HRQol varies 
in a different way across liver patients, which suggests that symptom severity items 
and symptom hindrance items measure different aspects of HRQol. these findings 
indicate that it is psychometrically sound to include both symptom severity items 
and symptom hindrance items into the ldsi 2.0.
validation of the liver disease symptom index 2.0
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aBstRaCt
Background: studies on Health Related Quality of life (HRQol) of chronic liver 
patients were performed in clinical populations. these studies included various 
disease stages but small variations in aetiology and no transplanted patients. we 
performed a large HRQol study in non-cirrhotic, cirrhotic and transplanted liver 
patients with sufficient variety in aetiology. we compared the generic HRQol and 
fatigue between liver patients and healthy controls and compared the disease-specific 
and generic HRQol and fatigue between non-cirrhotic, cirrhotic and transplanted 
liver patients, corrected for aetiology. 
Methods: Members of the dutch liver patient association received the short form-36, 
the liver disease symptom index 2.0 and the Multidimensional fatigue index-20. 
Based on reported clinical characteristics we classified respondents (n=1175) as non-
cirrhotic, compensated cirrhotic, decompensated cirrhotic or transplants. we used 
linear, ordinal and logistic regression to compare the HRQol between groups. 
Results: all liver patients showed a significantly worse generic HRQol and fatigue 
than healthy controls. decompensated cirrhotic patients showed a significantly 
worse disease-specific and generic HRQol and fatigue than non-cirrhotic patients, 
while HRQol differences between non-cirrhotic and compensated cirrhotic patients 
were predominantly insignificant. transplanted patients showed a better generic 
HRQol, less fatigue and lower probabilities of severe symptoms than non-cirrhotic 
patients, but almost equal probabilities of symptom hindrance.
Conclusions: HRQol in chronic liver patients depends on disease stage and 
transplant history. non-cirrhotic and compensated cirrhotic patients have a similar 
HRQol. decompensated patients showed the worst HRQol, while transplanted 
patients showed a significantly better HRQol than cirrhotic and non-cirrhotic 
patients. 
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i n the year 2000, 40.9% of the dutch population suffered from a chronic disease. in that same year, more than 800 dutch men and women died of a chronic liver disease 
(0.6% of year specific total mortality) 1. until today, the dutch liver patient association 
(nederlandse leverpatiënten vereniging (nlv)) and many other patient associations 
wwwwwht for recognition of disease related physical, mental and social problems of 
chronic patients. Quality of life research could contribute to a better understanding of 
these problems and may fulfil this quest for recognition.
one of the first studies done on Health Related Quality of life (HRQol) of chronic 
liver patients was conducted in 1979 and studied the effect of liver transplantation on 
HRQol of chronic liver patients 2. the study demonstrated that the quality of life of 
liver patients after transplantation ranged from poor to superior. in 1998, foster et al 
compared the HRQol of liver patients with viral hepatitis B and C and reported that 
social functioning, energy and fatigue and role limitations due to physical problems 
were significantly more impaired in hepatitis C patients 3. in more recent studies, 
the HRQol of different stages of liver disease were compared. younossi et al found 
an increasing impairment of generic HRQol with increasing disease severity, while 
Marchesini et al found that the most relevant determinants of impaired health status 
were severity of disease and muscle cramps 4-6.
these studies contributed substantially to our knowledge of the physical, social 
and mental problems of chronic liver patients. However, the majority of these studies 
was conducted in relatively small clinical populations and the comparisons between 
disease stages were adjusted for small or few aetiological groups. Moreover, none of 
these studies included liver transplant recipients in the study population.
therefore, to get a better understanding of the differences in HRQol between the 
various disease stages and the relation with transplanted liver patients, one must 
study a large liver patient population with a broad variety with respect to disease 
stage and aetiology. furthermore, the HRQol should be measured by a generic as 
well as a disease-specific questionnaire to give a profound insight in the differences 
in HRQol between disease stages 7 8.
our study offers an extensive overview of the HRQol of chronic liver patients. 
in contrast to the clinical populations in earlier studies, our collaboration with the 
dutch liver patient association gave us the opportunity to study the HRQol of 
large number liver patients, approaching a population level. the study population 
of 1175 members included various stages of cirrhosis and aetiologies as well as a 
large number of transplanted liver patients. it provided us with sufficient varied 
information to realise an HRQol comparison between non-cirrhotic, compensated 
cirrhotic, decompensated cirrhotic and transplanted liver patients, corrected for 
aetiology. 
another distinguishing feature of this study is that the HRQol information was 
generated by means of the liver disease symptom index 2.0 (ldsi), the short form-
36 (sf-36) and the Multidimensional fatigue index-20 (Mfi-20). other studies already 
used a combination of a generic and a disease-specific questionnaire 4,5. However, the 
ldsi provides, in contrast to other liver disease-specific questionnaires, information 
about the severity of symptoms and hindrance of these symptoms during daily 
activities. in an earlier study we demonstrated that the ldsi provides additional 
information on top of the sf-36 and the Mfi-20 (s.M. van der Plas, Quality of life 
Health related quality of life of non-cirrhotic, cirrhotic and transplanted liver patients
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Research, accepted for publication). the sf-36 and Mfi-20 were both validated in 
a clinical chronic liver patient population 9. therefore, the combination of these 
instruments forms a reliable and valid method to accomplish the following aims:1) to 
compare the generic HRQol and fatigue between chronic liver patients and healthy 
dutch controls and 2) to evaluate the differences in disease-specific HRQol, generic 
HRQol and fatigue between non-cirrhotic, compensated cirrhotic, decompensated 
cirrhotic and transplanted liver patients, corrected for aetiology. By evaluating the 
differences in disease-specific HRQol, we addressed the known groups validity 
of the ldsi across the various subgroups. the known groups validity is based on 
the principle that certain specified groups of patients, may be anticipated to score 
differently from others. we evaluated ldsi’s sensitivity for these differences.
MetHods
study population
in october 2000, all 2020 members of the nlv were approached for participation 
in this study and received a questionnaire by mail. the members included patients 
with a (history of ) liver disease as well as non-patients who joined the nlv because 
of involvement with liver patients in family, circle of acquaintances or work. after 
two months, non-responders received a new questionnaire. we closed the response 
period 5 months after the first mailing. as requested by the ethics Committee, 
members gave their informed consent by confirming their willingness to participate 
in the first question of the questionnaire. 
inclusion criteria were: 1) informed consent, 2) having a (history of ) liver disease 
and 3) aged 18 years or older at the moment of the study. to preserve the anonymity 
of the participants, the nlv withheld the coding of respondent numbers and member 
names, while the researcher withheld the completed questionnaires. the protocol 
was conform the ethical guidelines of the 1996 declaration of Helsinki and has been 
approved by the ethics Committee of the erasmus Medical Centre Rotterdam, the 
netherlands.
Measurement instruments
the disease-specific ldsi 2.0 includes 18 items. nine items measure the severity 
of: ‘itch’, ‘Joint pain’, ‘Pain in the right upper abdomen’, ‘sleepiness during the 
day’, ‘worry about family situation’, ‘decreased appetite’, ‘depression’, ‘fear of 
complications’ and ‘Jaundice’. nine other items measure the hindrance of these 
symptoms during daily activities. all items have ‘the last week’ as time frame and 
are scored on a 5-point scale ranging from ‘not at all’ to ‘to a high extent’. 
 apart from the ldsi, 6 additional items recommended by the nlv, were scored 
on the same 5-point scale. these items concerned: ‘Memory problems due to liver 
disease’, ‘Change of personality due to liver disease’, ‘Hindrance in financial affairs 
due to liver disease’, ‘involuntary change in use of time due to liver disease’, 
‘decreased sexual interest’ and ‘decreased sexual activity’. the ldsi as well as the 
extra nlv items have recently been validated in chronic liver patients and showed a 
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good feasibility, test-retest reliability and construct validity (van der Plas, Quality of 
life Research, accepted for publication).
the generic (dutch) sf-36 version 1.2, includes 8 multi-item scales on Physical 
functioning, Role limitations due to Physical problems (Role Physical), Bodily 
Pain, general Health, vitality, social functioning, Role limitations due to emotional 
problems (Role emotional) and Mental Health. the scale scores range from 0 to 100. 
a higher score indicates a better generic HRQol. sf-36 data of dutch healthy controls 
was available 10. 
the domain-specific Mfi-20 includes five 4-item scales: general fatigue, Physical 
fatigue, Reduction in activity, Reduction in Motivation and Mental fatigue and scale 
scores range from 4 to 20. Higher scores indicate more fatigue. Mfi-20 data of dutch 
healthy controls was available 11. Both the sf-36 and the Mfi-20 proved to be reliable 
and valid in dutch chronic liver patients 9.
a separate questionnaire was used to determine gender, age, marital status, 
education level, aetiology, duration of the liver disease, status of the liver disease(s) 
(cured, non-cured), presence of a liver transplant, presence of cirrhosis, presence 
or history of splenomegaly, ascites or oesophageal variceal bleedings, presence of 
oesophageal variceal bleedings or ascites in the year 2000, history of complications 
of cirrhosis (liver cancer or imminent coma), comorbidity (defined as the presence 
of diseases or disorders other than the liver disease that limit the respondent’s daily 
functioning), medication use and the amount of hours per week spent on work and 
activities with and without physical effort.
liver patient comparison groups 
due to the design of the study, respondents originated from all over the country and 
participated anonymously. therefore, we based the categorisation of respondents in 
disease stage groups (non-cirrhotic (nC), compensated cirrhotic (CC), decompensated 
cirrhotic (dC)) or the liver transplant group (ltX) on respondent-reported clinical 
characteristics (table 1). 
furthermore, we categorised respondents in 5 aetiology groups based on 
reported aetiologies: viral Hepatitis, autoimmune Hepatitis, Cholestatic diseases, 
Hemochromatosis and other liver diseases. transplanted respondents and 
respondents who considered themselves as cured were assigned to the groups ‘liver 
transplants’ and ‘Cured liver diseases’ respectively. 
we have validated the reliability of respondent-reported clinical characteristics, 
disease stage definitions and reported aetiologies in a pilot study conducted at 
our Hepatology outpatient clinic. Respondent-reported clinical characteristics 
and aetiologies demonstrated a good agreement between the test and the retest 
questionnaire (clinical characteristics: κ 0.85 [0.71, 0.94] to 0.97 [0.91, 1.03]; aetiologies: 
κ 0.71 [0.63, 0.79]) and a good agreement with hospital data (clinical characteristics: κ 
0.68 [0.45, 0.90] to 0.71 [0.53, 0.88]; aetiologies: κ 0.63 [0.55, 0.78]). Reported presence 
of cirrhosis showed a moderate agreement with hospital data (κ 0.52 [0.31, 0.73]). the 
assigned disease stage groups showed a lower agreement with the disease stages 
based on hospital data of the patients. the hospital data revealed that our disease 
stage definitions (which during the pilot did not include the criterion of recent ascites 
or variceal bleeding), disregarded the temporary state of the decompensated cirrhotic 
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stage: patients may become decompensated due to flare up of disease activity or 
inflammation, but can reverse to an apparently compensated state after treatment 
with diuretics or surgical interventions. 
during the current study, we took this temporary state of decompensated 
cirrhosis into account by including the criterion concerning: the presence of ascites 
or oesophageal variceal bleedings in the year 2000 (the year of the study), as extra 
item into the background questionnaire. this extra criterion distinguished recent 
decompensated cirrhotic patients from reversed decompensated cirrhotic patients. in 
the nlv population 43 compensated cirrhotic were defined as reversed decompensated 
cirrhotic patients (based on the absence of ascites and/or variceal bleedings in the 
year 2000 and the use of diuretics and/or propanolol at the moment of our study). 
the HRQol level of these patients fitted the HRQol level of the compensated 
cirrhotic group and not the HRQol level of decompensated patients. this indicated 
that these patients were correctly categorised as compensated cirrhotic patients.
Controls
Healthy dutch controls for the sf-36 (n=1715) originated from a nationwide, 
population-based health status survey with the standard version of the sf-36, 
conducted by the dutch organisation for applied scientific Research (tno). Controls 
were adult members of a random sample of dutch households, drawn from the 
national telephone registry. this registry included a somewhat larger percentage of 
men and a smaller category in the age of 15-25 years than the adult population in the 
netherlands. tno corrected for this imbalance by stating in the introductory letter 
that any adult member of the household could complete the questionnaire. a random 
set of introductory letters requested that the questionnaire had to be completed by a 
member of the household in the age of 15-25 years 10.
Healthy dutch controls for the Mfi-20 (n=139) originated from a study on fatigue 
and radiotherapy in cancer patients. Controls were adults from a non-selective 
sample of households taken from the telephone directories. as women are more 
frequently at home, researchers of this study prevented overrepresentation of women 
by interviewing the next person to have a birthday within that household 11.
statistical methods
we compared the generic HRQol of nC, CC, dC and ltX with the generic HRQol 
of the general dutch population. sf-36 scale scores were calculated by sf-36 scoring 
algorithms 12. we estimated mean sf-36 scale scores by general linear regression, in 
which we used the sf-36 scales as dependent outcome. a variable, which included 
the disease stage groups, transplanted group and controls served as independent 
determinant. Means were corrected for gender, age, marital status and education 
level. furthermore, we compared fatigue between nC, CC, dC and ltX and the 
general dutch population. the Mfi-20 scale scores were calculated by Mfi-20 scoring 
algorithms 13. we used general linear regression with the Mfi-20 scales as outcome 
to estimate mean Mfi-20 scale scores. again, the variable that included the various 
subgroups served as independent determinant. Means were corrected for gender, age 
and education level. 
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to compare the generic HRQol and fatigue between nC, CC, dC and ltX, we 
performed a linear regression in sPss 10.0 and in sas 8.0. sf-36 scales or Mfi-20 
scales served as dependent outcomes. Mean differences in sf-36 scale scores or mean 
differences in Mfi-20 scale scores were calculated between nC (reference) and CC, 
dC and ltX. of each scale, model-based standard errors in sPss were compared 
with robust standard errors provided by PRoC MiXed using the ‘empirical’-option 
in sas 8.0. Model-based standard errors in sPss were similar as robust standard 
errors in sas.
we evaluated the known groups validity of the ldsi symptom severity items 
across disease stages and the transplanted group by means of a proportional odds 
model for ordinal outcome with the PluM procedure in sPss 10.0. in every ldsi 
symptom severity item, the mean probability to score one of the five response 
categories (1=’no symptom’ to 5=’severe symptom’) was estimated per disease stage 
group or transplant group. we used the same model to evaluate the known groups 
validity of the extra nlv items. 
we evaluated the known groups validity of the ldsi symptom hindrance 
items across disease stages and the transplanted group by means of binary logistic 
regression. we estimated for each subgroup the odds ratio of being hampered by 
symptoms in daily activities (score=2 to 5), relatively to not being hampered (score=1) 
by these symptoms. we selected respondents who actually had the symptom 
(symptom severity score >1), since we assumed that only those respondents could 
have symptom hindrance. 
estimated differences, probabilities and odds ratios between subgroups were 
corrected for gender, age, education level, aetiology, use of liver disease medication, 
use of psychopharmaca and comorbidity. determinants were regarded as significant 
when p < 0.05.
Results
selection of the population
of the 2020 members approached for this survey, 1617 members returned the 
questionnaires. of these, 374 respondents were non-patient member, who joined the 
nlv because of involvement with liver patients in family, circle of acquaintances 
or work. in total 1243 patients had a (history of ) liver disease. according to the 
regulations of the ethics Committee, we excluded 21 patients who did not give 
informed consent. furthermore, we excluded forty-seven patients younger than 
18 years of age. in total 1175 respondents were included in the analysis. when we 
assumed that the percentage of patient members was equal in non-responders 
and responders (77%), than the total number of patient members in the total nlv 
population would be 1553 and the actual response (n=1243) would be around 80%. 
Population characteristics 
table 2 shows the baseline characteristics of the study population for non-cirrhotic, 
cirrhotic and transplanted liver patients and the characteristics of dutch healthy 
controls for the sf-36 and the Mfi-20. the total population of 1175 respondents of 
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table 1: Classification of disease stage groups and the transplanted group based on respondent-reported clinical 
characteristics. 
*) Patients can be defined as compensated cirrhotic in four clinical situations.
legend clinical characteristics:  
no:   absence of the clinical characteristic is an absolute condition for the concerning disease stage group or transplant group.
yes:   Presence of the clinical characteristic is an absolute condition for the concerning disease stage group or transplant 
group.
-  :  Presence or absence of the clinical characteristic is no absolute condition.
table 2 demographic and clinical characteristics of liver patients and controls.
nC=non-Cirrhosis, CC=Compensated Cirrhosis, dC=decompensated Cirrhosis, ltX=liver transplanted.
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which 678 (57.7%) were women had a mean age of 48.6 years (sd ± 12.7, range 18-81). 
in total 76% of these respondents spent on average 24.5 (sd ± 16.3) hours per week on 
a paid and/or voluntary job and spent on average 6.5 (sd ± 6.7) hours per week on 
physical activities like walking, cycling and gardening. 
all respondents with a liver transplant were assigned to the liver transplant group 
(n=186, 16.2%). the remaining respondents were mainly non-cirrhotic (42.5%) and 
compensated cirrhotic (34.0%). twenty-five respondents were not classified in one of 
the three disease stage groups or in the transplant group because of missing values in 
the classification items. 
More than one-fifth of the 1175 respondents had viral hepatitis (23.4%). of the 
57 (4.7%) respondents categorised as missing, 23 respondents reported cirrhosis as 
their liver disease, while 31 gave an unclear or insufficient description of their liver 
disease.
Comparison of generic HRQol and fatigue with dutch healthy controls
Respectively table 3 and 4 show the generic HRQol and fatigue of chronic liver 
patients compared to dutch healthy controls. the majority of the chronic liver 
patients reported a significantly impaired generic HRQol and significantly more 
fatigue compared to healthy controls (p < 0.05). only transplanted liver patients 
showed a similar level of mental health, bodily pain and reduction in motivation as 
healthy controls. 
Comparison of generic HRQol and fatigue between non-cirrhotic, cirrhotic and transplanted patients
figure 1 shows the mean differences in sf-36 scale scores between non-cirrhotic, 
cirrhotic and transplanted liver patients. the generic HRQol of chronic liver patients 
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figure 1: sf-36 scale score differences between non-cirrhotic (reference, set to zero), compensated cirrhotic, decompensated 
cirrhotic and transplanted liver patients. differences are corrected for gender, age, education level, aetiology, comorbidity, use 
of liver disease medication and use of psychopharmaca. 
negative differences: scale score of subgroup is lower (worse) than the scale score of non-cirrhotic patients.
Positive differences: scale score of subgroup is higher (better) than the scale score of non-cirrhotic patients.
*) scale score of subgroup is significantly lower or higher than the scale score of non-cirrhotic patients (p < 0.05).
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worsened with a worsening disease stage. non-cirrhotic and compensated cirrhotic 
patients showed few significant HRQol differences. Patients with decompensated 
cirrhosis mostly demonstrated a significantly worse generic HRQol than non-
cirrhotic patients. in contrast, transplanted patients scored on seven of the eight sf-
36 scales a significantly better HRQol than non-cirrhotic patients. fatigue showed the 
same pattern across the disease stages and the transplanted group (figure 2). 
known groups validity of the ldsi items
figure 3a to 3i illustrate the known groups validity of the ldsi symptom severity 
items. the probability to score higher than 1 on itch, pain in the right upper abdomen, 
sleepiness, worry about the family situation, decreased appetite, depression, fear 
and jaundice were highest for liver patients with decompensated cirrhosis. these 
probabilities were all significantly higher than the probabilities of the non-cirrhotic 
group (p=0.000 to p=0.002). Probabilities to score higher than 1 on joint pain were 
similar for all disease stages. Compensated cirrhotic patients had a significantly 
higher probability to score higher than 1 on itch (p=0.03), sleepiness (p=0.014) 
and jaundice (p=0.008) than non-cirrhotic patients. transplanted liver patients 
demonstrated significantly lower probabilities to score higher than 1 on itch, joint 
pain, pain in the right upper abdomen, sleepiness, worry about the family situation, 
decreased appetite, depression and fear of complications than non-cirrhotic patients 
(p=0.000 to p=0.002).
figure 4 shows the known groups validity of the ldsi symptom hindrance items. 
decompensated cirrhotic patients demonstrated for most symptoms significantly 
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figure 2: Mfi-20 scale score differences between non-cirrhotic, compensated cirrhotic, decompensated cirrhotic and 
transplanted liver patients. differences are corrected for gender, age, education level, aetiology, comorbidity, use of liver 
disease medication and use of psychopharmaca. 
negative differences: scale score of subgroup is lower (less severe) than the scale score of non-cirrhotic patients.
Positive differences: scale score of subgroup is higher (more severe) than the scale score of non-cirrhotic patients.
*) scale score of subgroup is significantly lower or higher than the scale score of non-cirrhotic patients (p < 0.05).
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figure 3a-i: Probabilities per ldsi symptom severity item per response category for all liver patients subgroups. 
Probabilities are corrected for gender, age, education level, aetiology, comorbidity, use of liver disease medication and use of 
psychopharmaca. 
nC=non-Cirrhosis, CC=Compensated Cirrhosis, dC=decompensated Cirrhosis, ltX=liver transplanted.
*) Probabilities of subgroup are significantly different from probabilities of non-cirrhosis (p < 0.05).
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higher odds ratios of symptom hindrance relatively to non-cirrhotic patients. 
Compensated cirrhotic patients showed only significantly higher odds ratios for 
hindrance of itch during the day and during sleep and hindrance of decreased 
appetite. transplanted patients showed a significantly lower odds ratio of hindrance 
of depression relatively to non-cirrhotic patients.
 
known groups validity of extra nlv items.
finally, we evaluated the known groups validity of the extra nlv items. the analysis 
showed that decompensated and compensated cirrhotic patients have a significantly 
higher probability of memory problems than non-cirrhotic patients (CC p=0.009, 
dC p=0.00), while transplanted patients show a significantly lower probability 
(p=0.009). the probability of a change in personality was, relatively to non-cirrhotic 
patients, significantly higher in the compensated and decompensated patient group 
(CC p=0.011, dC p=0.000). Compared to non-cirrhotic patients only decompensated 
patients showed significantly higher probabilities of financial limitations as a result 
of the liver disease (p=0.000). furthermore, the probability of ‘involuntary change 
in use of time’ increased significantly with a worsening disease stage (CC p=0.019, 
dC p=0.000). transplanted patients showed the lowest probability that the liver 
disease resulted in ‘involuntary change in use of time’ (p=0.000). the probabilities 
of decreased sexual interest were not significantly different between transplanted, 
compensated cirrhotic and non-cirrhotic patients, but decompensated cirrhotic 
patients showed a significantly higher probability of decreased sexual interest 
(p=0.000). decompensated as well as transplanted patients showed a significantly 
higher probability of decreased sexual activity compared to non-cirrhotic patients 
(dC p= 0.016, ltX p=0.001).
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figure 4: odds ratios (oR) for presence of symptom hindrance of transplanted and cirrhotic patients relatively to non-cirrhotic 
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disCussion
the aims of this study were: 1) the comparison of the generic HRQol and fatigue 
between chronic liver patients and healthy dutch controls and 2) to give a profound 
insight in the differences in disease-specific HRQol, generic HRQol and fatigue 
between non-cirrhotic, compensated cirrhotic, decompensated cirrhotic and 
transplanted liver patients, corrected for various aetiologies. 
we have shown that after correction for aetiology and other factors, generic 
HRQol, disease-specific HRQol and fatigue worsened with a worsening liver 
disease stage. 
However, non-cirrhotic and compensated cirrhotic patients mostly showed 
insignificant differences with respect to generic and disease-specific HRQol and 
fatigue. decompensated cirrhotic patients revealed a significantly lower generic 
HRQol, a higher probability of a worse disease-specific HRQol and more fatigue 
than non-cirrhotic patients. transplanted liver patients demonstrated a better generic 
HRQol, a lower probability of severe symptoms and less fatigue than non-cirrhotic 
and cirrhotic liver patients. However, their probability of symptom hindrance was 
often not significantly different from the non-cirrhotic group.
the worsening HRQol across disease stages found in our study is in line 
with earlier studies 4-6,14. also unal et al infrequently found significant differences 
in generic and disease-specific HRQol and fatigue between non-cirrhotic and 
compensated cirrhotic patients, although the trend across these two disease stages 
was reversed (compensated cirrhotic patients showed a better HRQol than non-
cirrhotic) compared to the trend found in our study 9. even after we had analysed the 
unal data with more advanced statistical methods, corrected for factors like sex, age, 
education and aetiology, the reversed trend remained. it should however be noted 
that this study and other earlier studies used different disease stage criteria (Child’s-
Pugh’s score and histological data), which hampered the inter-study comparison. 
the results of the current study indicate that the ldsi has a moderate to good 
known groups validity for the three disease stages and the transplanted liver 
patient group. the symptom severity items easily discriminated the decompensated 
patients and the transplanted patients from the non-cirrhotic patients. However, 
difficulties occurred regarding the discrimination between compensated cirrhotic 
and non-cirrhotic patients. the same problem emerged in the discrimination between 
compensated and non-cirrhotic patients by the symptom hindrance items. 
it is unclear if these difficulties should be attributed to a lack of sensitivity of 
the ldsi or to the natural characteristics of the compensated cirrhotic disease stage. 
after all, compensated cirrhotic patients may be asymptomatic for years or decades: 
ascites and neurological abnormalities are often absent and in general these patients 
have a good nutritional state. this may explain the similar HRQol in non-cirrhotic 
and compensated cirrhotic patients 6,15. one study already demonstrated the absence 
of a significant difference in HRQol between these two groups in a mixed population 
of chronic liver patients 14. But a significant difference between the disease-specific 
HRQol of non-cirrhotic and compensated cirrhotic was reported as well, although 
this study only included cholestatic liver patients 5. nevertheless, the ldsi items 
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more frequently distinguished between nC and CC patients than the various sf-36 
or Mfi-20 scales, which illustrated the disease-specific character of the ldsi.
until now, no other study directly compared the generic and disease-specific 
HRQol between transplanted liver patients and non-cirrhotic and cirrhotic liver 
patients. earlier studies repeatedly demonstrated that post-transplanted liver patients 
have a much better HRQol than pre-transplanted liver patients 16,17. However, our 
study specifically revealed that transplanted patients also have a better generic 
HRQol and less fatigue than non-cirrhotic and cirrhotic liver patients. nevertheless, 
the HRQol of transplanted patients was often significantly impaired, compared to 
the HRQol level of healthy controls. 
these results are in line with earlier research, which revealed that transplanted 
liver patients do have some physical problems, which indeed are experienced as 
limitations in daily life. although these limitations barely seem to affect their overall 
HRQol as transplanted patients have minimum of concern about physical problems, 
the presence of limitations may explain the impaired HRQol of transplanted patients 
18-22. the mental health of transplanted patients was comparable with the mental 
health of the healthy controls, which confirms earlier literature stating that the 
tension, depression and anger prevalence rates in transplanted patients were not 
notably different from the rates in controls 18,23. 
the high HRQol of transplanted liver patients compared to non-transplanted 
cirrhotic and non-cirrhotic patients may be explained by the difference in acquired 
social support. social support is of utmost importance as a resource of coping 
with chronic illness and may be beneficial for health outcome regardless of age 
24,25. for transplant recipients the psychological support in the transplantation and 
rehabilitation period provided by medical staff and family, is considered as one 
of the essentials of the transplant program, as social support influences the post 
transplantation survival and HRQol 18,26. However, for other chronic liver patients the 
enhancement of social support may be less considered as essential part of treatment. 
nevertheless, it could positively influence the HRQol by addressing negative 
feelings like low self-esteem or hopelessness resulting from the irreversibility of 
the pathological process and related disability. this potential hiatus in chronic liver 
disease management could be bridged by social network Mapping, which establishes 
a dialogue regarding individuals’ needs and possible sources of support 27.
despite of the fact that this study included a large population of chronic liver 
patients, this study design also had certain limitations. since 90% of our respondents 
originated from the netherlands, our study population could be regarded as a 
selected population. in another quality of life study conducted at our outpatient 
clinic, nearly a quarter of the participants were not originally dutch. due to the 
absence of other ethnic groups in our population, extrapolation of our results to 
outpatient populations should be done with caution.
additionally, it is unclear which liver patients are attracted by the patient 
association and how membership influences their HRQol. over representation of 
liver patients with a low HRQol, seeking contact with other liver patients may have 
led to an underestimation of HRQol, while other members’ social support may have 
influenced the measured HRQol in our population positively. furthermore, we 
lacked information about non-responders due to the design of the study. therefore, 
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responders may have been a selection of relatively healthy patients who felt well 
enough to complete the questionnaire, which may have led to an overestimation of 
HRQol. 
a last possible limitation of this study is that we had to depend on the respondents’ 
knowledge with respect to data about clinical symptoms and aetiologies. However, 
our pilot study at the outpatient clinic demonstrated that liver patients are very 
much aware of the clinical symptoms they have or have had and what type of liver 
disease they suffer from. as we have no reason to expect that members of a liver 
patient association are less informed, we are confident that this population-based 
study provided a reliable insight in the HRQol of chronic liver patients in western 
countries.  
we conclude that even after correction for aetiology and other factors, the generic 
and disease-specific HRQol and fatigue of chronic liver patients depends on the 
patient’s disease stage or transplant history. although the HRQol worsened with 
a worsening disease stage, non-cirrhotic and compensated cirrhotic patients barely 
showed significant differences in generic and disease-specific HRQol or fatigue. 
decompensated cirrhotic patients showed a significantly worse HRQol compared to 
non-cirrhotic patients. the HRQol of transplanted patients exceeded the HRQol of 
all other chronic liver patients, although it was still impaired compared to the HRQol 
of healthy controls. thus, chronic liver patients cannot be considered as one group 
for whom disease related problems have equal impact on their daily functioning. 
for a good medical treatment and an honest approach of chronic liver patients it is 
therefore important that the disease stage or the transplant history are taken into 
account. enhancing social support given by medical staff or family as part of chronic 
liver disease management may partly close the HRQol-gap between non-cirrhotic, 
cirrhotic and transplanted liver patients.
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aBstRaCt
Background: Most studies on Health Related Quality of life (HRQol) of chronic liver 
patients were conducted in small clinical populations or restricted to one aetiology 
or disease stage. there is still a need for a large study conducted in a liver patient 
population of various aetiologies and disease stages, approaching a population-
based study. we evaluated the impact of liver disease aetiology on generic HRQol, 
disease-specific HRQol and fatigue and compared the generic HRQol and fatigue 
between aetiological groups and healthy dutch controls.
Methods: Members of the dutch liver patient association completed the liver disease 
symptom index 2.0, short form-36, and Multidimensional fatigue index-20. we 
compared the HRQol between patients with viral hepatitis, autoimmune hepatitis, 
cholestatic diseases, hemochromatosis and other liver diseases by multivariate linear, 
ordinal and logistic regression. 
Results: Prominent differences between aetiological groups were especially found in 
comparisons with viral hepatitis and hemochromatosis patients. in the sf-36, viral 
hepatitis patients revealed a worse mental health than most other aetiological groups, 
whereas the ldsi showed significantly higher odds ratios of severe depression, severe 
worry and severe fear of complications. Hemochromatosis patients demonstrated 
significantly more joint pain and more limitations due to emotional problems with 
increasing age. 
Conclusions: severe joint pain, impaired role emotional functioning and impaired 
mental health distinguish hemochromatosis patients and viral hepatitis patients from 
other chronic liver patients.       
56
Chapter 4
i n the year 2000, 40% of the dutch population suffered from a chronic disease and more than 800 dutch men and women died of a chronic liver disease 1. until today, 
many patient associations, including the dutch liver patient association (nederlandse 
leverpatiënten vereniging (nlv)), fight for recognition of disease related physical, 
mental and social problems of chronic liver patients. Quality of life research may 
contribute to a better understanding of these problems and may fulfil this quest for 
recognition.
until now, research has given limited insight in the Health Related Quality of life 
(HRQol) differences between liver disease aetiologies. foster et al was the first to 
compare the HRQol of liver patients with hepatitis B or C. this study demonstrated 
that hepatitis C patients showed significantly more impairment of social functioning, 
energy and fatigue and role limitations due to physical problems than hepatitis B 
patients 2. later studies reported variable results concerning the effect of aetiology 
on HRQol. younossi et al found no significant HRQol differences between various 
aetiologies without cirrhosis, but did find significantly less impairment in cirrhotic 
cholestatic liver patients than in cirrhotic patients with hepatocellular disease 3. other 
studies reported no effect of aetiology on HRQol in cirrhotic patients and no effect of 
aetiology with respect to utility decrement regardless of the disease stage 4,5. 
although these studies contributed substantially to our understanding of HRQol 
in chronic liver patients, the majority of these studies were conducted in relatively 
small clinical populations or analyses were restricted to a certain disease stage. to 
increase our knowledge about the impact of various liver disease aetiologies on the 
HRQol there is still a need for a study in a large research population with a broad 
variety of aetiologies and various disease stages. this study should use a generic 
as well as a disease-specific questionnaire to get a profound insight in the HRQol 
differences between aetiologies 6,7.
our collaboration with the dutch liver patient association gave us the opportunity 
to evaluate the HRQol of chronic liver patients, approaching a population-based 
study. our study population of nlv members enabled us to evaluate the impact 
of various liver disease aetiologies on HRQol, since the population-size and the 
amount variation in the population regarding, aetiology, disease stage and other 
factors potentially influencing HRQol, permitted extensive correction for potential 
confounders. as recommended in the literature 6-8, we used the disease-specific 
liver disease symptom index and the generic short form-36. since fatigue is an 
important complaint of chronic liver patients 9-11, we added the domain-specific 
Multidimensional fatigue index-20.
our aim was to evaluate the impact of liver disease aetiology on generic HRQol, 
disease-specific HRQol and fatigue in patients with viral hepatitis, autoimmune 
hepatitis, cholestatic diseases, hemochromatosis and other liver diseases. therefore, 
we compared the disease-specific HRQol, generic HRQol and fatigue between 
the various aetiological groups, corrected for disease stage, use of liver disease 
medication, number of liver diseases per patient, comorbidity, gender, age, education 
level and use of psychopharmaca. additionally, we compared the generic HRQol 
and fatigue between the various aetiological groups and healthy dutch controls. 
the impact of viral hepatitis B and C infection on HRQol will be described in a 
separate paper.
Health related quality of life of liver patients with various aetiologies
57
MetHods
study population
in october 2000 all 2020 members of the nlv received a questionnaire by mail. 
the questionnaire consisted of the liver disease symptom index 2.0 (ldsi), the 
dutch short form-36 (sf-36), and the Multidimensional fatigue index-20 (Mfi-
20). nlv members included patients with a (history of ) liver disease as well as 
non-patients who joined the nlv because of involvement with liver patients in 
family, circle of acquaintances or work. after two months non-responders received 
a new questionnaire. we closed the response period 5 months after the first mailing. 
Members gave their informed consent by confirming their willingness to participate 
in the first question of the questionnaire. inclusion criteria were: 1) informed consent 
and 2) aged 18 years or older at the moment of the study 3) and having a (history of ) 
liver disease. to preserve the anonymity of the participants, the nlv withheld the 
coding of respondent numbers and member names, while the researcher withheld 
the completed questionnaires. the protocol was conform the ethical guidelines of the 
1975 declaration of Helsinki and approved by the ethics Committee of the erasmus 
MC Rotterdam, the netherlands.
Measurement instruments
the disease-specific ldsi 2.0 includes 18 items. nine items measure severity of: ‘itch’, 
‘Joint pain’, ‘Pain in the right upper abdomen’, ‘sleepiness during the day’, ‘worry 
about family situation’, ‘decreased appetite’, ‘depression’, ‘fear of complications’ 
and ‘Jaundice’. nine other items measure the hindrance of these symptoms to daily 
activities. all items have ‘the last week’ as time frame and are scored on a 5-point 
scale ranging from ‘not at all’ to ‘to a high extent’. apart from the ldsi, 6 additional 
items recommended by the dutch liver patient association, were scored on the 
same 5-point scale. these extra nlv items concern: ‘Memory problems due to liver 
disease’, ‘Change of personality due to liver disease’, ‘Hindrance in financial affairs 
due to liver disease’, ‘involuntary change in use of time’, ‘decreased sexual interest’ 
and ‘decreased sexual activity’. the ldsi as well as the extra nlv items have 
recently been validated in chronic liver patients at the outpatient clinic and in the 
nlv-population (van der Plas, Quality of life Research, accepted for publication). 
the generic sf-36, version 1.2, includes 8 multi-item scales on Physical 
functioning, Role limitations due to Physical problems (Role Physical), Bodily 
Pain, general Health, vitality, social functioning, Role limitations due to emotional 
problems (Role emotional) and Mental Health. the scale scores range from 0 to 100. 
a higher score indicates a better generic HRQol. 
the domain-specific Mfi-20 includes five 4-item scales: general fatigue, Physical 
fatigue, Reduction in activity, Reduction in Motivation and Mental fatigue and scale 
scores range from 4 to 20. Higher scores indicate more fatigue. Both the sf-36 and the 
Mfi-20 proved to be reliable and valid in dutch chronic liver patients 8
a separate questionnaire was used to determine gender, age, education level, 
aetiology, duration of the liver disease, status of the liver disease(s) (cured, non-
cured), presence of a liver transplant, presence of cirrhosis and presence or history 
of splenomegaly, ascites or oesophageal variceal bleedings, presence of oesophageal 
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variceal bleedings or ascites in the year 2000, history of complications of cirrhosis 
(liver cancer or imminent coma), comorbidity (defined as diseases or disorders other 
than the liver disease which limit the respondent’s daily functioning), medication use 
and the amount of hours per week spent on work and activities with and without 
physical effort.
liver patient comparison groups 
we categorised respondents into 5 aetiology groups: viral Hepatitis, autoimmune 
Hepatitis, Cholestatic liver diseases, Hemochromatosis and other liver diseases. 
furthermore, we categorised respondents into three disease stage groups: non-
cirrhosis, compensated cirrhosis and decompensated cirrhosis. as a consequence 
of the study design and anonymity of respondents, we based the categorisation in 
aetiology and disease stage groups on respondent-reported aetiologies and clinical 
characteristics in the questionnaire. 
Respondents who reported to have no cirrhosis and did not ever have splenomegaly, 
ascites or oesophageal variceal bleeding were classified as non-cirrhotic. Respondents 
who reported cirrhosis or ever had splenomegaly or ever had ascites or ever had 
oesophageal variceal bleeding, but not in the year 2000 (the year of investigation), were 
classified as compensated cirrhotic. Respondents who had had oesophageal variceal 
bleeding or ascites in the year 2000 were classified as decompensated cirrhotic.
in a pilot study conducted at our Hepatology outpatient clinic, reported aetiologies 
and clinical characteristics of disease stage demonstrated a good agreement between 
the test and the retest questionnaire (aetiologies: κ 0.71; clinical characteristics: 
κ 0.85 to 0.97) and a good agreement with hospital data (aetiologies: κ 0.63; clinical 
characteristics: κ 0.68 to 0.71). the assigned disease stage groups showed however a 
lower agreement with the disease stages based on hospital data of the patients. the 
hospital data revealed that our disease stage definitions disregarded the temporary 
state of the decompensated cirrhotic stage. with the current treatment modalities 
(diuretics or surgical interventions) decompensated cirrhotic patients often reverse to 
an apparently compensated state. 
in the current study we took this temporary state of decompensated cirrhosis 
into account by adding the criterion concerning: the presence of ascites or 
oesophageal variceal bleedings in the year 2000 (the year of the study), as extra item 
to the background questionnaire. in the nlv population 43 compensated cirrhotic 
patients could be defined as reversed decompensated cirrhotic patients based on the 
absence of ascites and/or variceal bleedings in the year 2000 and the use of diuretics 
and/or propanolol at the moment of our study. the HRQol level of the reversed 
decompensated cirrhotic patients fitted the HRQol level of the compensated cirrhotic 
group and not the HRQol level of decompensated patients and were therefore 
categorised as compensated cirrhotic patients.
Controls
Healthy dutch controls for the sf-36 (n=1715) originated from a nationwide, 
population-based health status survey with the standard version of the sf-36, 
conducted by the dutch organisation for applied scientific Research (tno). Controls 
were adult members of a random sample of dutch households, drawn from the 
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national telephone registry. this registry included a somewhat larger percentage of 
men and a smaller category in the age of 15-25 years than the adult population in the 
netherlands. tno corrected for this imbalance by stating in the introductory letter 
that any adult member of the household could complete the questionnaire. a random 
set of introductory letters requested that the questionnaire had to be completed by a 
member of the household between the ages of 15-25 years 12. 
Healthy dutch controls for the Mfi-20 (n=139) originated from a study on fatigue 
and radiotherapy in cancer patients. Controls were adults from a non-selective 
sample of households taken from the telephone directories. as women are more 
frequently at home, researchers of this study prevented overrepresentation of women 
by interviewing the next person to have a birthday within that household 13.
statistical methods
Crude sf-36 and Mfi-20 scale scores were calculated according to the sf-36 scoring 
algorithms 14 15. 
we used a general linear regression to estimate marginal mean sf-36 and Mfi-20 
scale scores for the aetiological groups and dutch healthy controls. sf-36 scales or 
Mfi-20 scales served as dependent outcome and aetiological groups (including the 
healthy controls as reference) as independent determinant. sf-36 scale scores were 
corrected for gender, age, education level and marital status. Mfi-20 scale scores were 
corrected for gender, age and education level. 
we also used linear regression to estimate the differences in generic HRQol or 
fatigue between aetiological groups. in this analysis we excluded healthy controls and 
corrected for gender, age, education level, disease stage, comorbidity, number of liver 
diseases per patient, use of liver disease medication and use of psychopharmaca. 
we used a proportional odds model for ordinal outcome by means of PRoC 
logistiC in sas 8.0. to estimate for each aetiological group the probability of a 
certain symptom severity outcome (1=no symptom, 2, 3, 4 or 5=severe symptom) 
measured by the ldsi. we used the same model to estimate for each aetiological 
group the probability of a certain outcome of the extra nlv items. 
Binary logistic regression estimated for each aetiological group the odds ratio of 
being hampered by symptoms in daily activities (score 2 to 5), relatively to not being 
hampered (score=1). for these analyses we selected only respondents with symptoms 
(symptom severity score >1). Probabilities and odds ratios were corrected for the 
same factors as the sf-36 and Mfi-20 scales score differences. interactions were 
significant if the overall p-value < 0.01 to avoid interactions by chance due to multiple 
testing. Moreover, the number of respondents in the interacting subcategories should 
be larger than 5% of the total population.
Results
selection of the population
of the 2020 members approached for this survey, 1617 members returned the 
questionnaires. of these, 374 respondents were non-patient member, who joined the 
nlv because of involvement with liver patients in family, circle of acquaintances or 
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work. in total 1243 had a (history of ) liver disease. assuming that the percentage of 
patient members is equal in non-responders and responders (77%), the total number 
of patient members would be 1553 and the actual response (n=1243) would be around 
80%. of the 1243, 1222 gave informed consent, but 47 were younger than 18 years of 
age. for this analysis we excluded 186 transplanted respondents and 71 respondents 
who reported them selves as cured, leaving 918 patient respondents for analyses.
Population characteristics 
table 1 shows the baseline characteristics of the study population and the dutch 
healthy controls for the sf-36 and the Mfi-20. the 918 respondents selected for 
analysis were mostly women (58.4%), had a mean age of 49 years (sd ± 12.6, range 
18-81), were married or living together and had lower secondary education level 
according to the isCed classification (unesCo general conference 1997). in total 
76% of these respondents spent on average 16.6 (sd ±22.7) hours per week on a paid 
and/or voluntary job and spent on average 7.2 (sd ±8.3) hours on physical activities 
like walking, cycling and gardening. 
a third of the respondents suffered from some form of viral hepatitis, mostly 
hepatitis C (66.9%) and B (29.5%). the cholestatic group included patients with 
primary biliary cirrhosis (63.4%) and primary sclerosing cholangitis (36.6%). the 
group ‘other liver diseases’ included patients with parenchymatous non-viral liver 
diseases (35.1%), vascular deformations (14.6%), congenital metabolic liver diseases 
(24.6%) and a mix of congenital anatomic liver diseases, benign and malignant 
malformations, cholelithiasis and secondary biliary cirrhosis (25.7%). fifty-seven 
respondents (6.2%) were classified as missing. in total 102 patients reported more 
than 1 liver disease. in total 590 (68.8%) of the patients reported next to their liver 
disease other comorbidity.
generic HRQol in chronic liver patients and dutch healthy controls
all aetiologies showed a significantly worse generic HRQol than healthy dutch 
controls on all sf-36 scales (figure 1). 
the upper diagonal of table 2 shows which sf-36 scales are significantly different 
between the aetiological groups. Most significant scale score differences were found 
when the viral hepatitis group was compared with one of the other aetiological 
groups. scale scores of the viral hepatitis group were often significantly lower 
indicating a worse HRQol than other aetiological groups. Compared to cholestatic 
liver patients, viral hepatitis patients scored significantly lower (worse) on all sf-36 
scales with score differences ranging from (-5.2 [-10.0,-0.3] with respect to bodily 
pain to -15.8 [-24.2, -7.3,] with respect to role limitations due to emotional problems). 
viral hepatitis patients showed a significantly worse vitality (-7.2 [-12.4, -2.1]), social 
functioning (-8.5 [-14.9, -2.0]) and more role limitations due to emotional problems 
(-18.9 [-28.2, -9.5]) than patients with autoimmune hepatitis. furthermore, viral 
hepatitis patients scored significantly lower (worse) with respect to mental health 
than patients with cholestatic diseases (-7.0 [-10.9, -3.04]), hemochromatosis (-7.7 [-
11.8, -2.5]) and patients with other liver diseases (-4.6 [-8.6, -0.6]). 
Hemochromatosis patients experienced significantly more bodily pain than all 
other aetiological groups (range bodily pain score differences: (-9.7 [-15.5, -4.0]) 
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table 1: demographic and clinical characteristics of liver patients and controls.
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compared to patients with viral hepatitis to (-14.9 [-21.1, -8.7]) compared to patients 
with cholestatic diseases). the aetiology dependent differences in role limitations due 
to emotional problems were modified by age. figure 2 shows the development of role 
emotional functioning by age for the various aetiologies. Hemochromatosis patients 
experienced a significantly stronger increase of role limitations due to emotional 
problems with increasing age than other aetiological groups (p < 0.006). 
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figure 1: Mean sf-36 scale scores of dutch healthy controls and chronic liver patients with various aetiologies, corrected for 
age, gender, education level and marital status.
*) aetiological groups have a significantly lower (worse) score than healthy controls on that specific scale (p < 0.05).
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figure 2: the adjusted Role emotional score by age (in years) for patients with autoimmune hepatitis, cholestatic diseases, 
viral hepatitis, other liver diseases and hemochromatosis. adjusted for gender, age, education level, disease stage, 
comorbidity, number of liver diseases, use of liver disease medication and use of psychopharmaca.
*) the steep decline in role emotional scores, especially observed in hemochromatosis patients (n=98) indicates: significantly 
more limitations in work or other daily activities due to emotional problems with increasing age than in other aetiological 
groups (p ≤ 0.006).
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fatigue in chronic liver patients and dutch healthy controls
all aetiologies showed a significantly worse fatigue than health dutch controls on all 
Mfi-20 scales (figure 3). 
the lower diagonal of table 2 shows which Mfi-20 scales are significantly 
different between the aetiological groups. again, the most significant scale score 
differences were found when the viral hepatitis group was compared with one of the 
other aetiological groups. in these cases viral hepatitis patients showed significantly 
higher scores, thus more fatigue. Compared to cholestatic patients, viral hepatitis 
patients showed significantly more fatigue on all scales ranging from +1.3 [0.25, 
2.4] with respect to general fatigue to +1.9 [0.8, 2.9] with respect to physical fatigue. 
Patients with autoimmune hepatitis demonstrated a significantly smaller reduction 
in activity (-1.5 [-2.7, -0.3]) and a smaller reduction in motivation (-1.4 [-2.4, -0.4]) 
than viral hepatitis patients, but a similar general, physical and mental fatigue. 
Hemochromatosis patients experienced on all Mfi-20 scales the same level of fatigue 
as viral hepatitis patients. 
Comparison of symptom severity and symptom hindrance between aetiologies
the upper diagonal of table 3 shows which aetiological groups differ significantly 
with respect to the odds ratios (oR’s) of severe symptoms. Relatively to other 
aetiological groups viral hepatitis revealed significantly higher oR’s of severe worry 
about the family situation (range: oR 2.02 [1.37, 3.00] relatively to other liver diseases 
table 2: significant differences in generic HRQol (sf-36, upper diagonal) and fatigue (Mfi-20, lower diagonal) between liver 
disease aetiological groups (p < 0.05). differences were corrected for gender, age, education level, disease stage, comorbidity, 
number of liver diseases, use of liver disease medication and use of psychopharmaca.
sf-36: Pf=physical functioning, RP=role limitations due to physical problems, BP=bodily pain, gH=general health, vi=vitality, 
sf=social functioning, Re=role limitations due to emotional problems, MH=mental health. Mfi-20: gf=general fatigue, 
Phf=physical fatigue, Ra=reduction in activity, RM=reduction in motivation, Mf=mental fatigue.
sf-36 scales:  
+) significantly higher score than reference group (=better HRQol on that scale).
-) significantly lower score than reference group (=worse HRQol on that scale).
Mfi-20 scales:
+) significantly higher score than reference group (=more severe fatigue on that scale).
-) significantly lower score than reference group (=less severe fatigue on that scale).
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to oR 2.8 [1.78, 4.29] relatively to cholestatic patients), severe depression (range: oR 
1.72 [1.16, 2.55] relatively to other liver diseases to oR 2.67 [1.70, 4.19] relatively to 
cholestatic diseases) and severe fear of complications (range: oR 1.54 [1.03, 2.29] 
relatively to ‘other liver diseases’ to oR 2.65 [1.69, 4.17] relatively to cholestatic 
diseases). the oR of severe fear was influenced by gender and comorbidity. in men, 
comorbidity significantly increased the oR of severe fear of complications relatively to 
men without comorbidity (oR 2.62 [1.62, 4.25]). additionally, men with comorbidity 
demonstrated significantly more fear of complications relatively to women with 
comorbidity (oR 1.54 [1.09, 2.16]). in hemochromatosis patients, the oR of severe 
joint pain was significantly higher relatively to all other aetiological groups (range: 
oR 1.89 [1.11, 3.22] relatively to autoimmune hepatitis to oR 4.28 [2.59, 7.05] relatively 
to cholestatic diseases). aetiological groups did not show significant differences with 
respect to severity of sleepiness during the day or severity of jaundice. 
the lower diagonal of table 3 shows which aetiological groups differ significantly 
with respect to the oR’s of symptom hindrance. Patients with autoimmune hepatitis, 
cholestatic diseases and other liver diseases demonstrated significantly lower oR’s 
of symptom hindrance than viral hepatitis patients. symptom hindrance was not 
significantly different between viral hepatitis and hemochromatosis patients in any 
of the symptoms. 
table 4 shows which aetiological groups have significantly higher or lower oR’s 
for the various complaints mentioned in the extra nlv items. viral hepatitis patients 
showed a significantly higher oR of severe change of personality due to the liver 
disease relatively to patients with hemochromatosis, cholestatic or other liver diseases 
(range: oR 1.56 [1.06, 2.29] relatively to other liver diseases to oR 2.21 [1.44, 3.40] 
relatively to cholestatic diseases). oR’s of severe memory problems, severe decreased 
sexual interest and severe decreased sexual activity were not significantly different 
among patients with viral hepatitis, autoimmune hepatitis, hemochromatosis or 
cholestatic diseases. 
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figure 3: Mean Mfi-20 scale scores of dutch healthy controls and chronic liver patients with various aetiologies, corrected for 
age, gender and education level. 
*) fatigue in aetiological groups is significantly more severe than in healthy controls on that specific scale (p < 0.05).
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table 3: significant odds ratios for symptom severity (upper diagonal) or symptom hindrance (lower diagonal) between 
aetiological groups (p < 0.05). odds ratios were corrected for gender, age, education level, disease stage, comorbidity, 
number of liver diseases, use of liver disease medication and use of psychopharmaca.
symptom severity items: 
+) the chance of a severe symptom for that specific aetiological group is significantly higher than for the reference group.
-) the chance of a severe symptom for that specific aetiological group is significantly lower than for the reference group.
symptom hindrance items:  
+) the chance of being hampered by the symptom is significantly higher for that specific aetiological than for the reference group.
-) the chance of being hampered by the symptom is significantly lower for that specific aetiological than for the reference group.
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other determinants associated with outcomes of the sf-36, ldsi and Mfi-20
in general: the female sex, a lower secondary education level or less, comorbidity, 
having more than 1 liver disease, use of liver disease medication and use of 
psychopharmaca are associated with a worse HRQol, more severe fatigue and 
higher oR’s of severe symptoms and symptom hindrance.
disCussion
our aim was to evaluate the impact of liver disease aetiology on generic HRQol, 
disease-specific HRQol and fatigue in chronic liver patients. Corrected for various 
factors including disease stage, patients with viral hepatitis showed generally 
a worse HRQol, but especially a worse mental health than other aetiological 
groups. viral hepatitis patients demonstrated significantly higher odds ratios of 
mental symptoms like worry about the family situation, depression and fear of 
complications. additionally, this patient group revealed significantly higher odds 
ratios of being hampered by various mental and physical symptoms during daily 
activities. Hemochromatosis patients revealed a significantly worse bodily pain, 
higher odds ratios of severe joint pain and their role emotional functioning steeply 
worsened with increasing age. Cholestatic liver patients generally showed a better 
generic HRQol and less fatigue than most other aetiological groups. all aetiological 
groups showed a significantly worse generic HRQol and more fatigue than healthy 
controls.
in our view, our study had the power to provide additional insight in the HRQol 
of chronic liver patients. the large study population included sufficient variation in 
aetiology and disease stage to allow HRQol comparisons by means of sophisticated 
statistical methods. a potential weakness of our study may be that the categorisation 
in aetiological and disease stage groups depended on data reported by the respondent. 
However, in our pilot study we demonstrated that inconsistencies between reported 
table 4: significant odds ratios between liver disease aetiological groups for complaints mentioned in the extra nlv 
items (p < 0.05). odds ratios were corrected for gender, age, education level, disease stage, comorbidity, number of liver 
diseases, use of liver disease medication and use of psychopharmaca.
+) the chance of a severe symptom for that specific aetiological group is significantly higher than for the reference group.
-) the chance of a severe symptom for that specific aetiological group is significantly lower than for the reference group.
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data and hospital data were few. therefore, we are confident that our respondents 
provided us with correct data about their aetiology and clinical characteristics. 
nevertheless, our results may have been influenced by potential selection biases. 
due to the design of the study no information about non-responders was available. 
Responders may have been a selection of relatively healthy patients who felt well 
enough to complete the questionnaire, which may have led to an overestimation of 
HRQol. furthermore, the patient association may attract liver patients with a low 
HRQol, although the social support given by other members may influence HRQol 
positively. these potential selection biases may have led to an over- as well as an 
underestimation of HRQol in our population. 
various other studies compared the HRQol differences between aetiologies. one 
study, conducted in chronic liver patients with various aetiologies (n= 353), reported 
that patients without cirrhosis (n=127) have a similar HRQol (measured by sf-36), 
regardless of the aetiology (viral or cholestatic). in cirrhotic patients, a significantly 
different HRQol was found between cholestatic patients and patients with 
hepatocellular liver disease, but not between cholestatic and viral hepatitis patients 
3. However, our post hoc analysis within the non-cirrhotic group showed that viral 
hepatitis patients do have a significantly worse physical functioning, vitality, social 
functioning, role emotional functioning and mental health than cholestatic patients. 
in cirrhotic patients, we found that viral hepatitis patients have a significantly worse 
HRQol than cholestatic patients in all sf-36 scales, except the bodily pain scale. 
differences in disease stage definitions as well as statistical methods may explain the 
different results of younossi et al. 
the same author measured utilities in chronic liver patients by means of the 
Health utility index-2. no significant differences between utility scores given by 
patients with viral, cholestatic and other liver diseases were found. However, the 
Hui-2 may measure a slightly different concept than the sf-36, as indicated by 
correlations between the Hui-2 and sf-36 results ranging from 0.59 to 0.71 4. finally, 
Marchesini et al pooled patients with viral hepatitis, PBC, autoimmune diseases and 
other liver diseases as non-alcoholic liver patients to compare their HRQol with the 
HRQol of alcoholic liver patients. no significant difference between alcoholic and 
non-alcoholic liver patients was found 5. 
in hemochromatosis patients, joint pain is a known complaint. twenty to fifty 
percent of the hemochromatosis patients older than 50 years of age develop arthritis 
in finger joints, which cannot be reversed and often progresses to other joints. 16-19. 
we hypothesized that this progressive pain might play a part in the worsening role 
emotional functioning with increasing age, since negative feelings like depression 
and fear could follow from the adverse consequences of accumulating health 
problems (disability hypothesis) 20. additionally, progressive pain might result in 
more emotional distress due to the dose-response relationship between pain and 
quality of life 21,22. a linear regression analysis in hemochromatosis patients showed 
indeed a significant positive relation between the bodily pain scale and the role 
emotional scale, although this finding does not allow conclusions about the direction 
of the relation between these two dimensions. 
with respect to viral hepatitis patients we demonstrated that these patients 
mostly suffered from an impaired mental health. Prominent differences with other 
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aetiological groups concerning the physical dimension were found less often. the 
relative importance of impaired mental health in viral hepatitis patients points 
at the possibility that mental impairment might induce physical health problems 
(psychosomatic hypothesis) in this patient group 20. intervention studies in viral 
hepatitis and hemochromatosis patients are needed to clarify if improvement of the 
impaired dimensions leads to improvement of other dimensions. 
in conclusion, this study increased our insight in the impact of liver disease 
aetiology on generic and disease-specific HRQol. Prominent differences between 
aetiological groups were especially found in comparisons with viral hepatitis and 
hemochromatosis patients. viral hepatitis patients revealed especially a worse 
mental health than all other aetiological groups, whereas hemochromatosis patients 
demonstrated significantly more bodily pain and more limitations due to emotional 
problems with increasing age. the potential interactions between physical and 
mental HRQol dimensions in these patient groups require more attention in research 
and clinical practice.
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aBstRaCt
Background: Health Related Quality of life (HRQol) of chronic hepatitis C patients 
has found to be impaired in clinical study populations. few studies directly compared 
the impact of hepatitis B or C infection on HRQol or have put the HRQol of viral 
hepatitis patients into perspective with other chronic diseases. we selected hepatitis 
B and C patients from a general liver patient population. our aim was to evaluate the 
impact of hepatitis B and hepatitis C infection on generic and disease-specific HRQol 
and fatigue. furthermore, we put the generic HRQol of viral hepatitis patients in 
perspective with other chronic liver patients and patients with diabetes mellitus and 
cancer.
Methods: Members of the dutch liver patient association completed the liver 
disease symptom index 2.0, short form-36, and Multidimensional fatigue index-20. 
our population (n=258) included patients with hepatitis B or hepatitis C with and 
without interferon therapy. we compared HRQol between the three subgroups by 
multivariate linear-, ordinal- and logistic regression. 
Results: Hepatitis C patients without interferon therapy showed an impaired role 
emotional functioning and mental health compared to hepatitis B patients, but 
also compared to other chronic liver and non-liver patients. interferon therapy 
significantly aggravated this impaired role emotional functioning and mental health 
and led to additional impairments of other HRQol dimensions. 
Conclusions: the difference in HRQol between hepatitis B patients and hepatitis 
C patients without interferon therapy was explained by the impaired emotional 
functioning and mental health found in hepatitis C patients. in hepatitis C patients 
with interferon therapy, additional and more severely affected HRQol elements 
contributed to this difference.
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i nfection with the hepatitis B virus as well as infection with the hepatitis C virus are major causes of chronic hepatitis. in immunocompetent adults, acute exposure 
to the hepatitis B virus leads in 2-10% percent to chronic hepatitis B, while acute 
exposure to hepatitis C leads in the vast majority (around 75%) to chronic hepatitis 
C 1,2. 
a cross-sectional population-based study on sera of 7373 dutch men and women 
in 1995-1996, demonstrated that 2.1% of the population had a history of hepatitis B 
infection. of these 0.2% was still infectious. almost 1 in thousand participants had a 
history of hepatitis C infection 3. 
 Many chronic hepatitis B patients are healthy carriers (50%). these patients have 
normal liver enzymes, a normal or near-normal liver histology, are asymptomatic and 
have an excellent prognosis. However, the other half of the chronic carriers may have 
evidence of continuous or intermittent active viral replication. of these patients, 15-
20% will develop cirrhosis within 5 years, which increases the risk of complications 
of the liver disease: ascites, variceal bleeding, encephalopathy and hepatocellular 
carcinoma. similar to chronic hepatitis B infections, chronic hepatitis C infections 
can be subclinical for at least two decades. as disease progression is mostly silent, 
the most frequent complaint is fatigue. also in chronic hepatitis C patients, the 
development of cirrhosis implies an increasing risk of liver related complications 1.
few studies directly compared the impact of hepatitis B or C infection on HRQol 
or have put the HRQol of viral hepatitis patients in perspective with other chronic 
liver and non-liver diseases. foster et al compared the HRQol of these patient groups 
by means of the sf-36 and revealed that hepatitis C patients are significantly more 
impaired with respect to social functioning, energy and fatigue and role limitations 
due to physical problems than hepatitis B patients 4. another study demonstrated 
that musculoskeletal pain and fatigue was more frequent in hepatitis C than in 
hepatitis B patients 5. these studies increased our knowledge about HRQol and 
symptom differences between these patient groups. However, to get a good insight 
in the impact of hepatitis B or C infection on HRQol, a larger population of viral 
hepatitis patients is needed with sufficient variation in disease stage and other factors 
influencing HRQol, to allow extensive adjustment. furthermore, a generic as well 
as a disease-specific questionnaire should be used to get a profound insight in the 
important symptoms and dimensions contributing to the HRQol of hepatitis B and 
C patients 6,7. Based on this knowledge, disease management could be adapted to the 
specific needs of these patient groups.
our collaboration with the dutch liver patient association gave us the opportunity 
to study the HRQol of patients with hepatitis B and C, selected from a general 
population of dutch chronic liver patients. our study population of nlv members 
enabled us to evaluate the adjusted impact of viral hepatitis B and C infection on 
HRQol, since the population-size and the amount variation in the population, 
permitted extensive adjustment for other factors. we used the disease-specific liver 
disease symptom index 2.0 and the generic short form-36. additionally, we used the 
Multidimensional fatigue index-20, as fatigue is an important complaint of patients 
with chronic hepatitis C 1,5,8. 
our first aim was to evaluate the impact of hepatitis B and hepatitis C infection on 
generic HRQol, disease-specific HRQol and fatigue. our second aim was to put the 
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HRQol of viral hepatitis B and C patients into perspective, by comparing the HRQol 
of patients with viral hepatitis with the HRQol of patients with other chronic liver 
and non-liver diseases such as diabetes mellitus and cancer.
MetHods
study population
in october 2000, all 2020 members of the dutch liver patient association (nederlandse 
leverpatiënten vereniging (nlv)) were approached for participation in this study 
and received a questionnaire by mail. the members included patients with a (history 
of ) liver disease as well as non-patients who joined the nlv because of involvement 
with liver patients in family, circle of acquaintances or work. after two months non-
responders received a new questionnaire. we closed the response period 5 months 
after the first mailing.
Members gave their informed consent by confirming their willingness to 
participate in the first question of the questionnaire. inclusion criteria for the current 
study were: 1) informed consent and 2) aged 18 years or older at the moment of the 
study 3) having a (history of ) liver disease, 4) reported viral hepatitis B or C. Patients 
who had a liver transplant and patients who reported themselves as cured were 
excluded.
to preserve the anonymity of the participants, the nlv withheld the coding 
of respondent numbers and member names, while the researcher withheld the 
completed questionnaires. the protocol was conform the ethical guidelines of the 
1996 declaration of Helsinki and approved by the ethics Committee of the erasmus 
Medical Center Rotterdam, the netherlands.
liver patient comparison groups 
we categorised respondents into two viral hepatitis groups: hepatitis B or hepatitis C.
Hepatitis C patients were categorised in patients with and without interferon 
therapy at the moment of the study. furthermore we categorised respondents in 
disease stage groups (non-cirrhosis, compensated cirrhosis and decompensated 
cirrhosis). 
as a consequence of the study design and anonymity of respondents, we based 
the categorisation in aetiology and disease stage groups on respondent-reported 
aetiologies and clinical characteristics in the questionnaire. Respondents who reported 
to have no cirrhosis and did not ever have splenomegaly, ascites or oesophageal 
variceal bleeding were classified as non-cirrhotic. Respondents who reported 
cirrhosis or ever had splenomegaly or ever had ascites or ever had oesophageal 
variceal bleeding, but not in the year 2000 (the year of investigation), were classified 
as compensated cirrhotic. Respondents who had had oesophageal variceal bleeding 
or ascites in the year 2000 were classified as decompensated cirrhotic.
in a pilot study conducted at our Hepatology outpatient clinic, reported 
aetiologies and clinical characteristics of disease stage demonstrated a good 
agreement between the test and the retest questionnaire (aetiologies: κ 0.71; clinical 
characteristics: κ 0.85 to 0.97) and a good agreement with hospital data (aetiologies: 
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κ 0.63; clinical characteristics: κ 0.68 to 0.71). the assigned disease stage groups (non-
cirrhosis, compensated cirrhosis and decompensated cirrhosis) showed however a 
lower agreement with the disease stages in hospital files of patients. the hospital data 
revealed that our disease stage definitions during the pilot, disregarded the temporary 
state of the decompensated cirrhotic stage, e.g. due to flare up of disease activity or 
inflammation. the current treatment modalities (diuretics or surgical interventions) 
help decompensated cirrhotic patients to reverse to an apparently compensated 
state. during the current study we took this temporary state of decompensated 
cirrhosis into account by adding the criterium concerning: the presence of ascites or 
oesophageal variceal bleedings in the year 2000 (the year of the study), as extra item to 
the background questionnaire. this item would discriminate reversed decompensated 
cirrhotic patients from recent decompensated cirrhotic patients. 
other comparison groups
we compared the generic HRQol of viral hepatitis patients with the generic HRQol 
of patients with diabetes mellitus and cancer. Patients with diabetes mellitus (n=60) 
originated from a sample of 4024 patients older than 18 years of age, approached 
by 60 general practitioners in the southern and eastern parts of the netherlands 
9. Patients with cancer (n=485), originated from a sample of patients with breast, 
colorectal or lung cancer with a life expectancy of at least 4 months, recruited from 
the outpatient clinics of the departments of internal medicine and radiotherapy of the 
antoni van leeuwenhoek hospital in amsterdam 10.
Measurement instruments
for HRQol measurement we used the dutch versions of the liver disease 
symptom index version 2.0 (ldsi), the short form-36 (sf-36), version 1.2 and 
the Multidimensional fatigue index (Mfi-20). in addition, we obtained personal 
background information by a separate questionnaire. 
the disease-specific ldsi 2.0 includes 18 items. nine items measure severity 
of: ‘itch’, ‘Joint pain’, ‘Pain in the right upper abdomen’, ‘sleepiness during the 
day’, ‘worry about family situation’, ‘decreased appetite’, ‘depression’, ‘fear of 
complications’ and ‘Jaundice’. nine other items measure the hindrance of these 
symptoms to daily activities. all items have ‘the last week’ as time frame and are 
scored on a 5-point scale ranging from ‘not at all’ to ‘to a high extent’. apart from the 
ldsi, 6 additional items recommended by the dutch liver patient association, were 
scored on the same 5-point scale. the items concern: ‘Memory problems due to liver 
disease’, ‘Change of personality due to liver disease’, ‘Hindrance in financial affairs 
due to liver disease’, ‘involuntary change in use of time’, ‘decreased sexual interest’ 
and ‘decreased sexual activity’. the ldsi as well as the extra items have recently been 
validated in chronic liver patients at the outpatient clinic and in the nlv-population 
(van der Plas, Quality of life Research, accepted for publication). 
the generic sf-36 includes 8 multi-item scales on Physical functioning, Role 
limitations due to Physical problems (Role Physical), Bodily Pain, general Health, 
vitality, social functioning, Role limitations due to emotional problems (Role emotional) 
and Mental Health. the scale scores range from 0 to 100. a higher score indicates a better 
generic HRQol. sf-36 data of dutch healthy controls are available 10. 
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the domain-specific Mfi-20 includes five 4-item scales: general fatigue, Physical 
fatigue, Reduction in activity, Reduction in Motivation and Mental fatigue. scale 
scores range from 4 to 20. Higher scores indicate more fatigue. Mfi-20 data of dutch 
healthy controls are available 11. Both the sf-36 and the Mfi-20 proved to be reliable 
and valid in dutch chronic liver patients 12.
a separate questionnaire was used to determine gender, age, education level, marital 
status, aetiology, duration of the liver disease, status of the liver disease(s) (cured, 
non-cured), presence of a liver transplant, presence of cirrhosis and presence or 
history of splenomegaly, ascites or oesophageal variceal bleedings, presence of 
oesophageal variceal bleedings or ascites in the year 2000, history of complications 
of cirrhosis (liver cancer or imminent coma), comorbidity (defined as the presence 
of diseases or disorders other than the liver disease that limit the respondent’s daily 
functioning), medication use and the average number of hours per week spent on 
work and activities with and without physical effort.
statistical methods
demographic and clinical characteristics were compared between hepatitis groups 
by t-test (approximate normal variables), Mann-whitney test (for continuous non-
normal variables) and χ2-test (for categorical variables). Crude sf-36 and Mfi-20 
scale scores were calculated according to the sf-36 and Mfi-20 scoring algorithms 
respectively 13,14. Crude sf-36 and Mfi-20 scale scores were compared between 
hepatitis B and C patients per disease stage. differences were regarded as significant 
when p ≤ 0.005 to prevent significant results due to multiple testing.
to estimate adjusted differences in generic HRQol or fatigue between patients 
with viral hepatitis B and viral hepatitis C patients with and without interferon 
therapy, we performed a general linear regression. sf-36 scales or Mfi-20 scales 
served as dependent variables. the hepatitis groups and correction factors served as 
independent determinants.
we compared the ldsi symptom severity between hepatitis B and hepatitis C 
with and without interferon therapy with a proportional odds model for ordinal 
outcome by means of PRoC logistiC in sas 8.0. this model estimated for each 
viral hepatitis group the probability of a certain symptom severity outcome (1=no 
symptom, 2, 3, 4 or 5=severe symptom). the same model was used to analyse the 
extra nlv items. 
Binary logistic regression estimated for each of the three viral hepatitis groups 
the odds ratio of being hampered by symptoms in daily activities (score 2 to 5), 
relatively to not being hampered (score=1) by these symptoms. we assumed that 
only respondents with symptoms could have symptom hindrance, therefore we 
selected respondents who actually had the symptom (symptom severity score > 1). 
the symptom hindrance variables served as the dependent outcomes, viral hepatitis 
groups and correction factors as independent determinants. odds ratios for symptom 
hindrance were estimated per subgroup. 
differences, probabilities and odds ratios were regarded as significant when p < 
0.05 and were corrected for gender, age, education level, average number of hours 
paid work conducted per week, disease stage, comorbidity, number liver diseases, use 
of liver disease medication and use of psychopharmaca. interactions were regarded 
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as significant if the overall p-value < 0.01. additionally, the number of respondents in 
the interacting subcategories should be larger than 5% of the total population.
Results
selection of the population
of the 2020 members approached for this survey, 1617 members returned 
questionnaires. of these, 374 respondents were non-patient member who joined the 
nlv because of involvement with liver patients in family, circle of acquaintances 
or work. in total 1243 had a (history of ) liver disease. in total 258 patients met the 
inclusion criteria for the current study. 
Population characteristics 
table 1 shows the baseline characteristics of the liver patient population and the 
dutch healthy controls for the sf-36 and the Mfi-20. Patients with viral hepatitis C 
were significantly (p=0.04) older and had a higher education (p=0.04) than patients 
with hepatitis B. the hepatitis B group included significantly more men (p=0.03). 
other demographic characteristics were not significantly different between the 
table 1: demographic and clinical characteristics of liver patients.
a significantly different between hepatitis B and hepatitis C patients, p=0.04
b significantly different between hepatitis B and hepatitis C patients, p=0.03
c significantly different between hepatitis B and hepatitis C patients, p=0.04
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two patient groups. Hepatitis B patients spent per week significantly more hours 
on a paid job (25.8 hours, p=0.01) than hepatitis C patients (16.3 hours). Hepatitis 
B as well as hepatitis C patients spent 6.5 hours per week on physical activities like 
walking, cycling and gardening. at the time of the study, 22 hepatitis C patients used 
interferon. none of the hepatitis B patients used interferon.
with respect to the non-liver chronic patients, more than half of the sample (54.2%) 
that included the diabetes mellitus patients had an age lower than 50. the total sample 
included 67.6% women, but the mean age and gender distribution of the diabetes 
mellitus patients is unknown. the mean age of cancer patients originating from the 
antoni van leeuwenhoek hospital was 57.3 (± 12.1) years and the sample included 58% 
women. the majority of these patients had breast cancer (35%) or lung cancer (31%). 
generic HRQol and fatigue in patients with viral hepatitis B and C
figure 1 and figure 2 respectively, show the uncorrected and corrected difference in 
generic HRQol and fatigue between patients with viral hepatitis B and C. Hepatitis C 
patients were categorised in hepatitis C patients with and without interferon therapy. 
Compared to hepatitis B patients, hepatitis C patients with interferon therapy showed 
significant impairments on almost all sf-36 and Mfi-20 scales (p < 0.03). the most 
severe impairment concerned the amount of limitations due to emotional problems. 
also hepatitis C patients without interferon therapy reported a significantly impaired 
mental health (p=0.005) and more limitations due to emotional problems (p=0.041) 
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figure 1: uncorrected difference in generic HRQol between patients with hepatitis B and hepatitis C (overall) and corrected 
differences in generic HRQol between patients with viral hepatitis B, hepatitis C with interferon therapy and hepatitis C 
patients without interferon therapy. Corrected for gender, age, education level, disease stage, use of liver disease medication, 
comorbidity, number liver diseases per patient, use of psychopharmaca and average number of hours paid work conducted 
per week.
negative difference: lower (worse) scale score than scale score of hepatitis B patients.
*) scale score is significantly lower (worse) than scale score of hepatitis B patients (p < 0.05).
#) scale score of hepatitis C patients with interferon therapy is significantly lower (worse) than scale score of hepatitis C 
patients without interferon therapy (p ≤ 0.001).
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than hepatitis B patients. However, the impairments regarding vitality, social 
functioning, role emotional functioning, role physical functioning and four of the five 
fatigue scales found in hepatitis C patients with interferon therapy were significantly 
worse than in hepatitis C patients without interferon therapy (p ≤ 0.002). 
table 2 shows the comparison of crude sf-36 and Mfi-20 scores between patients 
with hepatitis B and C per disease stage. in non-cirrhotic patients, hepatitis C patients 
showed a significantly worse physical and social functioning and more role limitations 
due to emotional problems (p ≤ 0.005) than hepatitis B patients. none of the disease 
stages showed significant differences in fatigue between hepatitis B and C. 
after correction for baseline factors and categorisation by interferon use, non-
cirrhotic hepatitis C patients with interferon (n=14) showed a worse social functioning 
(p=0.000), more limitations due to emotional problems (p=0.002) and a worse 
mental health (p=0.047) than non-cirrhotic hepatitis B patients. Hepatitis C patients 
without interferon (n=146) and hepatitis B showed no significant differences. in the 
compensated cirrhotic group, 6 hepatitis C patients used interferon. no differences 
were found between this group and hepatitis B patients, but hepatitis C patients 
without interferon (n=67) did show a worse mental health (p=0.014) and a more severe 
reduction in activity (p=0.009) and motivation (p=0.018) than hepatitis B patients in the 
same disease stage. in decompensated cirrhotic patients, we only corrected for gender 
due to small numbers. solely hepatitis C patients without interferon therapy showed a 
significantly impaired mental fatigue compared hepatitis B patients (p=0.049).
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figure 2: uncorrected difference in fatigue between patients with hepatitis B and hepatitis C (overall) and corrected differences 
in fatigue between patients with viral hepatitis B, hepatitis C with interferon therapy and hepatitis C patients without interferon 
therapy. Corrected for gender, age, education level, disease stage, use of liver disease medication, comorbidity, number liver 
diseases per patient, use of psychopharmaca and average number of hours paid work conducted per week.
Positive difference=higher scale score (more severe fatigue) than scale score of hepatitis B patients.
negative difference=lower scale score (less severe fatigue) than scale score of hepatitis B patients.
*) scale score is significantly higher (more severe) than scale score of hepatitis B patients (p < 0.05).
#) scale score of hepatitis C patients with interferon therapy is significantly higher (more severe) than 
scale score of hepatitis C patients without interferon therapy (p ≤ 0.002).
Health related quality of life of patients with viral hepatitis B or C
81
symptom severity and symptom hindrance in patients with viral hepatitis B and C
also with respect to symptom severity we categorised hepatitis C patients by 
interferon use. Both interferon users and non-users showed a significantly higher 
odds ratio of severe depression than hepatitis B patients (oR users: 10.67 [3.72, 30.57], 
oR non-users: 2.13 [1.10, 4.13]). furthermore, hepatitis C patients with interferon 
showed a significantly higher oR of severely decreased appetite (oR 3.28 [1.17, 9.15]) 
table 2: uncorrected sf-36 and Mfi-20 scale scores of hepatitis B and C patients per disease stage.
‡) scores are significantly different between hepatitis B and C (p ≤ 0.005). 
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and a significantly higher oR of involuntary change in time spending (oR 3.04 [1.05, 
8.82]), while non-users reported a significantly higher odds ratio of being hampered 
by joint pain during daily activities (oR 3.37 [1.05, 10.8]) compared to hepatitis B 
patients.
Comparison of generic HRQol between patients with viral hepatitis and chronic patients with liver and 
non-liver diseases
we compared the corrected mean HRQol measured by the sf-36, between patients 
with viral hepatitis B and C (with and without interferon) and other chronic liver 
patients. furthermore, we used the crude sf-36 scale means for cancer and diabetes 
mellitus to put the HRQol of hepatitis B and C patients in perspective (figure 
3). Hepatitis C patients without interferon showed a significantly worse mental 
health and role emotional functioning than other chronic liver patients, although 
hemochromatosis patients revealed a similar role emotional functioning. also 
compared to patients with diabetes mellitus and cancer, these hepatitis C patients 
reported more limitations due to emotional problems and a worse mental health. 
interferon therapy significantly aggravated the generic HRQol of hepatitis C 
patients. in contrast, hepatitis B patients reported a similar emotional functioning 
and mental health as other liver patients and a better emotional functioning and 
mental health than cancer patients.
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figure 3: Corrected mean sf-36 scale scores for patients with viral hepatitis B, hepatitis C with interferon therapy, hepatitis 
C patients without interferon therapy, hemochromatosis patients and patients with other liver diseases (cholestatic diseases, 
autoimmune hepatitis and remaining liver diseases) compared with crude mean sf-36 scale scores for patients with diabetes 
mellitus and cancer. Means of liver patients are corrected for gender, age, education level, disease stage, use of liver disease 
medication, comorbidity, number liver diseases per patient, use of psychopharmaca and average number of hours paid work 
conducted per week.
Hepatitis C patients with and without interferon therapy showed a significantly worse mental health and role emotional 
functioning than most other chronic liver patients (p < 0.05). Role emotional functioning was not significantly different 
between hepatitis C patients and hemochromatosis patients. Compared to diabetes mellitus and cancer patients, both 
hepatitis C subgroups reported more limitations due to emotional problems and a worse mental health.
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disCussion
the aims of this study were to evaluate the impact of hepatitis B and hepatitis C 
infection on generic HRQol, disease-specific HRQol and fatigue and to compare the 
generic HRQol between patients with viral hepatitis, other chronic liver patients and 
patients with chronic non-liver diseases, such as diabetes mellitus and cancer. 
as interferon or interferon-based therapy could influence the mental health of 
hepatitis C patients 15-17, we compared the HRQol of hepatitis B patients with the 
HRQol of hepatitis C patients with interferon therapy or without interferon therapy. 
the HRQol of hepatitis C patients with interferon therapy was significantly more 
severly affected than the HRQol of hepatitis C patients without interferon therapy. 
yet, hepatitis C patients with interferon as well as without interferon therapy showed 
a significantly impaired role emotional functioning and mental health compared to 
hepatitis B and other chronic liver patients. Hepatitis C patients with and without 
interferon also showed an impaired role emotional functioning and mental health 
compared to patients with diabetes mellitus and cancer.
few other studies compared the HRQol between hepatitis B and hepatitis C 
patients. foster et al compared the HRQol measured by the sf-36, of non-cirrhotic 
patients with viral hepatitis B or C, who had not taken antiviral medication within the 
past 6 months. Hepatitis C patients revealed a significantly worse social functioning, 
vitality and more role limitations due to physical problems than hepatitis B patients 4. 
However, these findings were uncorrected for confounders. in the current study, 
we found no significant differences between non-cirrhotic hepatitis B and hepatitis 
C patients without interferon. in the compensated cirrhotic group we did find a 
significantly more severe reduction in activity and motivation and a significantly 
worse mental health in hepatitis C patients without interferon. 
it is still unclear why the mental/emotional health of hepatitis B patients is less 
affected. in hepatitis C patients changes in brain metabolism, may cause cognitive 
impairments like impaired concentration and speed of working memory. these 
cognitive problems could result in less effective performance in daily activities, that 
could indirectly cause depression and anxiety 18-21. Hepatitis B patients demonstrated 
less signs of altered cerebral metabolism than hepatitis C patients 22. 
furthermore, it has also been reported that hepatitis B patients experienced less 
frequently an interferon-induced depression than hepatitis C patients 23. the effect 
of interferon use on mental health of hepatitis C patients might be confounded by a 
chronic condition predating the onset of viral infection and the use of interferon 24. 
a recent study reported that almost 50% of the 630 patients with the diagnosis HCv, 
used anti-depressant in the pre-diagnostic period, against 38.4% in controls (p < 0.001) 
25. Moreover, depressive symptoms and psychiatric morbidity have been associated 
with intravenous drug use, whereas intravenous drug use has been associated with 
hepatitis C infection. therefore, history of drug usage could confound the impaired 
mental health found in hepatitis C patients 24,26,27. in our study we did not investigate 
the intravenous drug history of respondents. 
another factor that could play an important part in the impairment of mental 
health of hepatitis C patients is the diagnosis of hepatitis C its self. a recent study, 
based on a screening among women who received hepatitis C virus contaminated 
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blood products in 1977, included 87 PCR positive women with a chronic HCv 
infection and 68 PCR negative women considered to have a spontaneous self-limited 
infection. despite the PCR negative status of the 68 women, a similar proportion of 
women reached the criteria for depression and anxiety (9.8%) as in the PCR positive 
group (9.6%). this suggest that the sudden diagnosis with an infectious chronic 
disease, associated with intravenous drug usage, may have caused great concern to 
these women and can be regarded as a stressful event which could influence mental/
emotional health 28. 
furthermore, we lacked insight in the social network of hepatitis C patients. in 
a qualitative study, hepatitis C patients showed distress due to actual loss or fear of 
losing partners, friends and family due to perceived social stigma, associated with 
societal fear of contagions or the relation of hepatitis C with intravenous drug use 
29,30. another study showed that of the 257 hepatitis C patients, 147 experienced 
stigmatisation that they attributed to their disease. the likelihood of stigmatisation 
was independent of mode of infection, professional status, education and age, but 
was significantly associated with depression, anxiety and worsened quality of life 31.
a final factor that may have influenced the mental health of hepatitis might 
be the hepatitis C awareness campaigns. Hepatitis C awareness campaigns may 
create, next to awareness, also fear of cirrhosis, hepatocellular carcinoma and liver 
transplantation, although around 80% of all chronic hepatitis C patients will never 
develop cirrhosis and 95% will never develop hepatocellular carcinoma 32.
in conclusion, hepatitis C patients without interferon therapy showed an 
impaired emotional functioning and mental health compared to hepatitis B patients, 
but also compared to other chronic liver patients and patients with diabetes mellitus 
and cancer. interferon therapy significantly aggravated this impaired emotional 
functioning and mental health and led to additional impairments of other HRQol 
dimensions. during hepatitis C consultations, besides attention for physical 
impairments, attention should be given to psychological impairments in this patient 
group. 
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aBstRaCt
Background: since most studies on Health Related Quality of life (HRQol) of 
chronic liver patients were conducted in small clinical populations, there is still a 
need for a large study on HRQol of chronic liver patients of various aetiologies and 
disease stages that approaches a population-based study. 
Methods: eleven hundred and seventy-five members of the dutch liver patient 
association completed the generic short form-36 and the disease-specific liver 
disease symptom index 2.0. we used multivariate linear, ordinal and logistic 
regression to compare the HRQol between disease stages (also including transplanted 
liver patients) and various aetiologies.
Results: liver patients demonstrated a significantly reduced HRQol compared to 
healthy controls, corrected for gender, age, education and marital status. Compared 
to non-cirrhotic patients, compensated cirrhotic patients showed few significant 
reductions in generic HRQol (2 of 8 sf-36 scales) and infrequently significantly 
higher odds ratios of severe symptoms (3 of the 9 ldsi symptoms). decompensated 
cirrhotic patients showed a marked reduction in generic and disease-specific 
HRQol (7 of 8 sf-36 scales, 8 of 9 ldsi symptoms), whereas transplanted patients 
had a significantly better generic and disease-specific HRQol than non-cirrhotic 
patients (7 of 8 sf-36 scales, 8 of 9 ldsi symptoms). with respect to aetiology, we 
found that hemochromatosis patients experienced significantly more bodily pain 
and significantly more limitations due to emotional problems with increasing age 
than other aetiological groups. Hepatitis C patients showed a severely impaired 
mental health than other chronic liver patients that was significantly aggravated by 
interferon therapy. the relative contributions of selection, disease-specific factors and 
environmental factors to the findings in these patient groups were discussed. 
Conclusions: this population-based study confirms the reduction in HRQol in all 
liver patients and provides additional insight in the relative HRQol level of specific 
liver patient groups and in the disease-specific HRQol reduction in patients with 
hemochromatosis and hepatitis C.
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M ost studies on Health Related Quality of life (HRQol) of chronic liver patients have been conducted in clinical populations. Many studies assessed the 
quality of life of liver patients before and after transplantation using standardized 
quality of life questionnaires. one year after transplantation, most transplanted 
patients demonstrated a practically normal quality of life, although not as good as 
the general population 1. younossi et al studied the impact of disease severity on 
HRQol and found an increasing impairment of generic HRQol with worsening of 
disease severity from non-cirrhosis to advanced cirrhosis 2-4. according to Marchesini 
et al, muscle cramp was the most relevant determinant of impaired health status in 
cirrhotic patients 5. 
studies reported variable results concerning the effect of aetiology on HRQol. 
several studies failed to find a significant difference in HRQol between various 
aetiological groups, although one study demonstrated significantly less impairment 
in cirrhotic cholestatic liver patients than in cirrhotic patients with hepatocellular 
disease 2-5. furthermore, several studies compared the HRQol of hepatitis B or C 
patients, which revealed that hepatitis C patients are significantly more impaired 
with respect to social functioning, energy and fatigue and role limitations due to 
physical problems, musculoskeletal pain and fatigue than hepatitis B patients 6,7.
these studies contributed substantially to our understanding of HRQol in 
chronic liver patients. However, the majority of these studies were conducted in 
relatively small clinical populations or restricted to a certain disease stage, leaving 
limited space for correction for other potentially confounding factors of HRQol. for 
that reason, there was still a need for large study on HRQol in chronic liver patients 
that approached a population-based study. 
our collaboration with the dutch liver patient association gave us the opportunity 
to study the HRQol of a large general population of chronic liver patients. our study 
population included sufficient variation regarding disease stage, aetiology, and other 
factors influencing HRQol, permitting extensive adjustment for confounding factors. 
Based on this population we evaluated the impact of disease stage, liver transplant 
and aetiology on the HRQol of chronic liver patients. Results of sub-studies 
addressing specific elements have been published previously in specific domains 8. 
in this article we give a summary of our findings for the practicing hepatologist.
MetHods
study population
in october 2000 all 2020 members of the dutch liver patient association (nederlandse 
leverpatiënten vereniging (nlv)) were approached for participation in this study 
and received a questionnaire by mail. the members included patients with a (history 
of ) liver disease as well as non-patients who joined the nlv because of involvement 
with liver patients in family, circle of acquaintances or work. after two months non-
responders received a new questionnaire. we closed the response period 5 months 
after the first mailing. Members gave their informed consent by confirming their 
willingness to participate in the first question of the questionnaire. inclusion criteria 
were: 1) informed consent and 2) aged 18 years or older at the moment of the study 3) 
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and having a (history of ) liver disease. to preserve the anonymity of the participants, 
the nlv withheld the coding of respondent numbers and member names, while the 
researcher withheld the completed questionnaires. the protocol was conform the 
ethical guidelines of the 1996 declaration of Helsinki and approved by the ethics 
Committee of the erasmus MC Rotterdam, the netherlands.
Measurement instruments
one of the questionnaires we used for this study was the short form-36 (sf-36). 
this generic quality of life instrument includes 8 multi-item scales on Physical 
functioning, Role limitations due to Physical problems (Role Physical), Bodily 
Pain, general Health, vitality, social functioning, Role limitations due to emotional 
problems (Role emotional) and Mental Health. the scale scores range from 0 to 100. 
a higher score indicates a better generic HRQol. sf-36 data of dutch healthy controls 
are available 9. 
objective physiological and clinical outcomes are poorly associated with the 
patient’s health perceptions 10,11. therefore, additional information about the way 
liver patients experience their symptoms and how these specific symptoms affect 
their daily activities could be important for disease management. Moreover, this 
disease-specific information could be helpful in the interpretation of sf-36 findings. 
for this reason, we developed the liver disease symptom index. after validation 
we adjusted the initial version, which resulted in the liver disease symptom index 
2.0 (ldsi). the ldsi 2.0 includes 18 items. nine items measure severity of: ‘itch’, 
‘Joint pain’, ‘Pain in the right upper abdomen’, ‘sleepiness during the day’, ‘worry 
about family situation’, ‘decreased appetite’, ‘depression’, ‘fear of complications’ 
and ‘Jaundice’. nine other items measure the hindrance of these symptoms to daily 
activities. all items have ‘the last week’ as time frame and are scored on a 5-point scale 
ranging from ‘not at all’ to ‘to a high extent’. the ldsi has recently been validated 
in chronic liver patients at the outpatient clinic and in the nlv-population (van der 
Plas, accepted for publication in Quality of life Research). 
a separate questionnaire was used to determine gender, age, education level, 
marital status, aetiology, duration of the liver disease, status of the liver disease(s) 
(cured, non-cured), presence of a liver transplant, presence of cirrhosis and presence 
or history of splenomegaly, ascites or oesophageal variceal bleedings, presence 
of oesophageal variceal bleedings or ascites in the year 2000, history of other 
complications of cirrhosis (liver cancer or encephalopathy), comorbidity (defined 
as the presence of diseases or disorders other than the liver disease which limit the 
respondent’s daily functioning), medication use and the amount of hours per week 
spent on work and activities with and without physical effort.
liver patient comparison groups 
due to the design of the study, respondents originated from all over the country and 
participated anonymously. therefore, we based the categorisation of respondents 
in disease stage groups and aetiological groups on respondent-reported clinical 
characteristics. 
for the categorisation in disease stage groups, we categorised respondents 
who reported absence of cirrhosis and did not ever have splenomegaly, ascites or 
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oesophageal variceal bleeding, as non-cirrhotic (nC). Respondents who reported 
cirrhosis or ever had splenomegaly or ever had ascites or ever had oesophageal 
variceal bleeding, but not in the year 2000 (the year of investigation), were classified 
as compensated cirrhotic (CC). Respondents who had had oesophageal variceal 
bleeding or ascites in the year 2000 were classified as decompensated cirrhotic (dC). 
Patients with a transplant history were assigned to the transplant group (ltX).
 furthermore, we categorised respondents in 5 aetiology groups, namely: viral 
Hepatitis, autoimmune Hepatitis, Cholestatic diseases, Hemochromatosis and other 
liver diseases. in this categorisation, transplanted respondents and respondents who 
considered themselves as cured were excluded. for the final study, we selected in the 
viral hepatitis group all patients with viral hepatitis B or viral hepatitis C. 
we have validated the reliability of respondent-reported clinical characteristics, 
disease stage definitions and respondent-reported aetiologies in a pilot study 
conducted at our Hepatology outpatient clinic. Reported clinical characteristics 
and aetiologies demonstrated a good agreement between the test and the retest 
questionnaire (clinical characteristics: κ 0.85 [0.71, 0.94] to 0.97 [0.91, 1.03]; aetiologies: 
κ 0.71 [0.63, 0.79]) and a good agreement with hospital data (clinical characteristics: κ 
0.68 [0.45, 0.90] to 0.71 [0.53, 0.88]; aetiologies: κ 0.63 [0.55, 0.78]). 
the disease stage groups defined on the basis of clinical characteristics, showed a 
lower agreement with the disease stages in the patients’ hospital records. the hospital 
data revealed that our initial disease stage definitions (which did not include the 
criterion of recent ascites or variceal bleeding), disregarded the possible temporary 
state of the decompensated cirrhotic stage: patients may become decompensated 
due to flare up of disease activity or inflammation, but can reverse to an apparently 
compensated state after treatment with diuretics or surgical interventions. in the 
current study, we included an extra item concerning: the presence of ascites or 
oesophageal variceal bleedings in the year 2000 (the year of the study). this extra 
criterion distinguished recent decompensated cirrhotic patients from reversed 
decompensated cirrhotic patients. 
in the nlv population 43 compensated cirrhotic were defined as reversed 
decompensated cirrhotic patients (based on the absence of ascites and/or variceal 
bleedings in the year 2000 and the use of diuretics and/or propanolol at the moment 
of our study). we found that the HRQol level of these patients fitted the HRQol 
level of the compensated cirrhotic group and not the HRQol level of decompensated 
patients and categorised these patients as compensated cirrhotic patients.
other comparison groups
we compared the HRQol of chronic liver patients with the HRQol of dutch patients 
with other chronic diseases and dutch healthy controls. 
Patients with diabetes mellitus (n=60) originated from a sample of 4024 patients 
older than 18 years of age, approached by 60 general practitioners in the southern and 
eastern parts of the netherlands 12. Patients with cancer (n=485), originated from a 
sample of patients with breast, colorectal or lung cancer recruited from the outpatient 
clinics of departments of internal medicine and radiotherapy of the antoni van 
leeuwenhoek hospital in amsterdam with a life expectancy of at least 4 months 9.
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Healthy dutch controls for the sf-36 (n=1715) originated from a nationwide, 
population-based health status survey with the standard version of the sf-36, 
conducted by the dutch organisation for applied scientific Research (tno). 
Controls were adult members of a random sample of dutch households, drawn from 
the national telephone registry 9. 
statistical methods
we used various regression methods to compare generic HRQol (general linear 
regression), symptom severity (proportional odds models for ordinal outcome) and 
symptom hindrance (logistic regression) between disease stage groups (non-cirrhosis, 
compensated cirrhosis, decompensated cirrhosis and transplanted), between 
aetiological groups (viral hepatitis, autoimmune hepatitis, cholestatic diseases, 
hemochromatosis and other liver diseases) and between viral hepatitis groups (viral 
hepatitis B and C). sf-36 scales and ldsi items served as dependent outcome. the 
comparison groups served as independent determinants. 
differences, probabilities and odds ratios were corrected for gender, age, 
education level, disease stage, comorbidity, number of liver diseases per patient, 
use of liver disease medication and use of psychopharmaca. in case of comparisons 
between viral hepatitis subgroups, we also corrected for average number of hours 
paid work conducted per week. 
we used general linear regression to estimate the differences in generic HRQol 
or fatigue between chronic liver patients and healthy controls. differences were 
corrected for gender, age, education level and marital status.
in the results section, a sf-36 scale score difference between a subgroup and the 
reference group has been expressed as percentage. a percentage expresses how much 
higher or lower a scale score of a subgroup is relatively to the reference group.
Results
selection of the population
of the 2020 members approached for this survey, 1617 members returned the 
questionnaires. of these, 374 respondents were non-patient member, who joined the 
nlv because of involvement with liver patients in family, circle of acquaintances or 
work. in total 1243 patients had a (history of ) liver disease. we excluded 21 patients 
who did not give informed consent according to the regulations of the ethics 
Committee. forty-seven respondents were excluded due to their age of <18 years. in 
total 1175 respondents were included in the analysis. 
Population characteristics
table 1 shows the demographic and clinical characteristics of the nlv population.
a large majority (90%) of the respondents reported the netherlands as country of 
birth. in total 76% of these respondents spent on average 24.5 (sd ± 16.3) hours per 
week on a paid and/or voluntary job and spent on average 6.5 (sd ± 6.7) hours per 
week on physical activities like walking, cycling and gardening. the viral hepatitis 
groups included mostly hepatitis C (66.9%) and B (29.5%). the cholestatic group 
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included patients with primary biliary cirrhosis (63.4%) and primary sclerosing 
cholangitis (36.6%). the group ‘other liver diseases’ included patients with 
parenchymatous non-viral liver diseases (35.1%), vascular deformations (14.6%), 
congenital metabolic liver diseases (24.6%) and a mix of congenital anatomic liver 
diseases, benign and malignant malformations, cholelithiasis, and secondary biliary 
cirrhosis (25.7%). fifty-seven respondents (6.2%) were classified as missing. in total 
102 (8.7%) patients reported more than 1 liver disease. sixty-eight percent (n=746) 
reported comorbidity apart from their liver disease. 
impact of disease stage and liver transplantation on HRQol
figure 1a shows the differences in sf-36 scale scores between non-cirrhotic, 
compensated cirrhotic, decompensated cirrhotic and transplanted patients and the 
scale scores of dutch healthy controls, corrected for gender, age, education level 
and marital status. scale scores of liver patients were all significantly impaired and 
table 1: demographic and clinical characteristics of liver patients and controls.
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differences between liver patients and healthy controls increased with an increasing 
severity of disease stage. transplanted patients showed in 6 of the 8 sf-36 scales a 
significantly worse generic HRQol. scores of transplanted liver patients were 8.0% 
(vitality) to 31% (limitations in daily activities due to physical problems (role physical 
scale)) lower than the scores of healthy controls. 
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figure 1a: differences in sf-36 scale scores between transplanted, non-cirrhotic and cirrhotic liver patients and healthy 
controls (reference group, set to zero). differences are corrected for gender, age, education level and marital status.
negative differences: scale score of subgroup is lower (worse) than the scale score of healthy controls
*) scale score in subgroup is not significantly lower (worse) than the scale score of healthy controls.
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figure 1b: sf-36 scale score differences between non-cirrhotic (reference, set to zero), compensated cirrhotic, 
decompensated cirrhotic and transplanted liver patients. differences are corrected for gender, age, education level, aetiology, 
comorbidity, use of liver disease medication and use of psychopharmaca. 
negative differences: scale score of subgroup is lower (worse) than the scale score of non-cirrhotic patients.
Positive differences: scale score of subgroup is higher (better) than the scale score of non-cirrhotic patients.
*) scale score of subgroup is significantly lower or higher than the scale score of non-cirrhotic patients (p < 0.05).
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differences between these three disease stages and the transplanted group were 
assessed in more detail after correction for gender, age, education level, aetiology, 
comorbidity, use of liver disease medication and use of psychopharmaca (figure 1b). 
transplanted liver patients revealed a 2% (physical functioning) to 36% (general 
health) better generic HRQol compared to non-cirrhotic patients. non-cirrhotic 
and compensated cirrhotic patients barely showed significant differences, but 
decompensated cirrhotic patients reported a 6% (mental health) to 66% (role physical) 
reduction in generic HRQol compared to non-cirrhotic patients. 
similar observations across these subgroups were found with respect to disease-
specific HRQol 8.
impact of aetiology on HRQol
figure 2a shows the generic HRQol measured in the various liver disease aetiological 
groups and healthy controls, corrected for gender, age, education level and marital 
status. all aetiological groups showed a significantly lower generic HRQol than 
healthy controls; the generic HRQol of patients with hemochromatosis and viral 
hepatitis was most affected, both with on average 30% lower scores than healthy 
controls.
figure 2b shows the differences in generic HRQol between the various aetiological 
groups after further correction for baseline factors such as disease stage, comorbidity, 
number of liver diseases, use of liver disease medication and use of psychopharmaca, 
and confirms the differences between aetiological groups shown in figure 2a. 
Hemochromatosis patients experienced significantly more bodily pain (16%-
23%) than other aetiological groups, while the disease-specific ldsi pointed out that 
hemochromatosis patients had significantly higher odds ratios of severe joint pain 
relatively to other aetiological groups (relatively to: viral hepatitis: oR 2.27 [1.44, 
3.57], autoimmune hepatitis oR 1.89 [1.11, 3.22], Cholestatic diseases: oR 4.28 [2.59, 
7.05], other liver diseases: oR 3.37 [2.03, 5.58]). 
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figure 2a: Mean sf-36 scales scores for various aetiological groups and healthy controls. Means are corrected for gender, 
age, education level and marital status. 
*) on all sf-36 scales, aetiological groups have a significantly impaired HRQol compared to healthy controls (0.000 ≤ p ≤ 0.045).
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furthermore, the limitations in daily activities due to emotional problems (role 
emotional functioning) of hemochromatosis patients increased with increasing age 
(figure 3). the effect of age on experienced limitations during daily activities due to 
emotional problems was significantly stronger in hemochromatosis patients than the 
age effect in other aetiological groups (p=0.000 to p=0.006).
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figure 2b: Mean sf-36 scales scores for various aetiological groups. Means are corrected for gender, age, education level, 
disease stage, comorbidity, number of liver diseases, use of liver disease medication, use of psychopharmaca. 
*) Hemochromatosis patients have significantly more bodily pain than all other aetiological groups (0.000 ≤ p ≤ 0.001). viral 
hepatitis patients have a significantly worse role emotional functioning (0.000 ≤ p ≤ 0.052) and significantly worse mental 
health than most other aetiological groups (0.001≤ p ≤ 0.06).
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figure 3: the adjusted Role emotional score by age (in years) for patients with autoimmune hepatitis, cholestatic diseases, 
viral hepatitis, other liver diseases and hemochromatosis. adjusted for gender, age, education level, disease stage, 
comorbidity, number of liver diseases, use of liver disease medication and use of psychopharmaca.
*) the steep decline in role emotional scores, especially observed in hemochromatosis patients (n=98) indicates: significantly 
more limitations in work or other daily activities due to emotional problems with increasing age than in other aetiological 
groups (p ≤ 0.006).
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 viral hepatitis patients showed significantly more limitations due to emotional 
problems (13%-26%) and significantly worse mental health (7-10%) than other 
aetiological groups. 
the disease-specific ldsi specifically pointed out that viral hepatitis patients 
had significantly higher oR’s of severe worry about the family situation, severe 
depression and severe fear of complications relatively to all other aetiological groups 
(worry: oR over all: 2.39 [1.76, 3.24]; depression: oR over all: 2.01 [1.48, 2.74]; fear: 
oR over all: 2.09 [1.54, 2.87]).
 
the viral hepatitis group included 74 hepatitis B patients and 184 hepatitis C patients. 
Hepatitis C patients demonstrated significantly lower sf-36 scores regarding physical 
functioning (-11%), social functioning (-14%), role emotional functioning (-28%) and 
mental functioning (-14%) than hepatitis B patients (figure 4a). More specifically, the 
ldsi showed in hepatitis C patients significantly higher odds ratios of severe worry 
about the family situation (oR 1.84, Ci 95% [1.04, 3.29]) and severe depression (oR 
2.56, Ci95% [1.34, 4.87]) than in hepatitis B patients.
additionally, we compared the HRQol of hepatitis B patients with hepatitis C 
patients with interferon therapy (n=22) and without interferon therapy (n=161) at 
the moment of the study (figure 4b). Hepatitis C patients with interferon showed 
significant impairments on almost all sf-36 scales. the most severe impairment 
concerned the amount of limitations due to emotional problems (score: -77% 
relatively to hepatitis B). Hepatitis C patients without interferon therapy also reported 
a significantly lower (worse) mental health score (-12%) and role emotional score 
(-19%) than hepatitis B patients. in line with these findings, both interferon users 
and non-users showed a significantly higher odds ratio of severe depression than 
hepatitis B patients (oR users: 10.67 [3.72, 30.57], oR non-users: 2.13 [1.10, 4.13]) in 
the ldsi. 
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figure 4a: Mean sf-36 scales scores for viral hepatitis B (n=74) and viral hepatitis C patients (n=184). Means are corrected 
for gender, age, education level, disease stage, comorbidity, number of liver diseases, use of liver disease medication, use of 
psychopharmaca and average number of hours paid work per week.
*) viral hepatitis C patients demonstrated a significantly worse physical functioning (p=0.022), social functioning (p=0.038), 
role emotional functioning (p=0.003) and mental functioning (p=0.001) than patients with viral hepatitis B.
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HRQol of chronic liver patients compared to non-liver patients
in figure 5a, we compared the corrected generic HRQol measured by the sf-
36 between patients with hepatitis B, hepatitis C (without interferon therapy), 
hemochromatosis and other chronic liver patients (including: cholestatic diseases, 
autoimmune hepatitis and remaining liver diseases). Hepatitis C patients without 
interferon showed significantly lower (worse) scores with respect to mental health 
(on average -11%) and role emotional functioning (on average -23%) than most other 
liver patient subgroups. the role emotional score of hemochromatosis patients was 
not significantly different. Hemochromatosis patients still showed significantly 
more pain than hepatitis C without interferon, hepatitis B and the other chronic liver 
patients combined.
in figure 5b, we used the crude sf-36 scale means for cancer and diabetes mellitus 
to put the generic HRQol of chronic liver patients in perspective. also compared 
to patients with diabetes mellitus or cancer, hepatitis C patients without interferon 
therapy reported lower scores regarding limitations due to emotional problems (-
33% compared to diabetes mellitus and -5% compared to cancer patients) and mental 
health (-12% compared to diabetes mellitus and -8% compared to cancer patients), 
whereas hemochromatosis patients reported lower scores regarding bodily pain (-
22% compared to diabetes mellitus and cancer).
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figure 4b: Mean sf-36 scales scores for viral hepatitis B (n=74) and viral hepatitis C patients with interferon therapy (n=22) 
and without interferon therapy (n=161). Means are corrected for gender, age, education level, disease stage, comorbidity, 
number of liver diseases, use of liver disease medication, use of psychopharmaca and average number of hours paid work per 
week.
*) Mean scales scores of hepatitis C patients without interferon therapy, were only significantly lower (worse) than scale 
scores of hepatitis B patients with respect to role emotional functioning (p=0.041) and mental health (p=0.001). 
Mean scale scores of hepatitis C patients with interferon therapy, were significantly lower (worse) than all mean scale scores 
of hepatitis B patients (0.000 ≤ p ≤ 0.029), except regarding bodily pain.
in hepatitis C patients with interferon therapy, scores regarding vitality, social functioning, role emotional functioning and role 
physical functioning were significantly worse than in hepatitis C patients without interferon therapy (p ≤ 0.002). 
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figure 5a: Mean sf-36 scales scores of patients with viral hepatitis C without interferon therapy, viral hepatitis B, 
hemochromatosis and other liver diseases (cholestatic diseases, autoimmune hepatitis, remaining liver diseases). Means 
are corrected for gender, age, education level, disease stage, comorbidity, number of liver diseases, use of liver disease 
medication, use of psychopharmaca and average number of hours paid work per week. 
*) also compared to most other aetiological groups, hepatitis C patients without interferon therapy showed a significantly 
worse role emotional functioning (0.000 ≤ p ≤ 0.014) and a worse mental health (0.000 ≤ p ≤ 0.019). Role emotional 
functioning was not significantly different between hepatitis C patients and hemochromatosis patients.
Hemochromatosis patients still showed significantly more bodily pain than other groups (p ≤ 0.012).
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figure 5b: Mean sf-36 scales scores of patients with viral hepatitis C without interferon therapy, hemochromatosis and 
other liver diseases (cholestatic diseases, autoimmune hepatitis, viral hepatitis B and remaining liver diseases) corrected for 
gender, age, education level, disease stage, comorbidity, number of liver diseases, use of liver disease medication, use of 
psychopharmaca and average number of hours paid work per week. Corrected sf-36 scale scores of chronic liver patients are 
compared with crude sf-36 scale scores of patients with diabetes mellitus and cancer.
also compared to patients with diabetes mellitus or cancer, hepatitis C patients without interferon therapy reported more 
limitations due to emotional problems and a worse mental health. Hemochromatosis patients reported more bodily pain than 
patients with diabetes mellitus and cancer.
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disCussion
Main findings
in this survey among dutch liver patients, approaching a population-based study, 
the HRQol of specific liver patient subgroups has been put in perspective with 
other liver patients, non-liver patients and healthy controls. on the one hand, this 
study confirmed findings of smaller clinical studies; on the other hand new findings 
emerged thanks to the large size of the study population and the use of both a generic 
and a disease-specific questionnaire.
transplanted liver patients demonstrated a better HRQol than non-cirrhotic and 
cirrhotic liver patients, but did not equal the HRQol level of healthy controls. non-
cirrhotic and compensated cirrhotic patients barely showed significant differences 
whereas decompensated patients showed the worst HRQol on all dimensions. 
Hemochromatosis patients exhibited significantly more bodily pain and with 
increasing age more limitations due to emotional problems than other aetiological 
groups. viral hepatitis C patients without interferon therapy, showed a significantly 
worse role emotional functioning and mental health than other chronic liver and non-
liver patients; interferon therapy was associated with a further significant reduction 
in HRQol 
limitations and advantages of the study
our study had advantages but also limitations compared to earlier and mostly 
clinical studies. on the one hand, the large study population and the amount of 
variation regarding disease stage, aetiology and other factors allowed analyses 
with extensive correction for confounders; additionally the study design prevented 
referral bias. on the other hand, members of the dutch liver patients association may 
have been a selected population of chronic liver patients, and respondents may have 
been selection of relatively healthy patients. 
a final limitation is that for data on clinical characteristics and aetiology we 
depended on respondent-reported clinical data. to test the potential bias of the latter, 
we performed a pilot study that showed a good agreement between respondent-
reported clinical and aetiological data and data derived from the hospital records, 
allowing us to rely on respondent-reported data.
explanation of the findings
impact of disease stage
non-cirrhotic and compensated cirrhotic patients showed small and often non-
significant differences in generic disease-specific HRQol. this finding confirmed 
earlier reports regarding the absence of subjective complaints in compensated 
cirrhotic patients 13. in ldsi items, large proportions of non-cirrhotic as well as 
compensated cirrhotic patients reported absence of symptoms (on average 57% and 
53% respectively). However, this may also indicate that the ldsi lacks sensitivity to 
detect small differences between these groups.
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decompensated cirrhotic patients showed the worst HRQol in all dimensions. 
the HRQol level in decompensated cirrhotic patients may have been overestimated 
by the classification of reversed decompensated cirrhotic patients; i.e. patients with 
ascites and/or variceal bleeding in the past but not in the year of the study using 
diuretics and/or propanolol at the moment of our study. we included these patients 
in the compensated cirrhotic group because their HRQol level equalled the HRQol 
level of compensated cirrhotic patients. inclusion of reversed decompensated cirrhotic 
patients in the decompensated cirrhotic group would have reduced the abnormalities 
in both the compensated and the decompensated group. 
impact of liver transplantation
we found that transplanted liver patients demonstrated a far better HRQol than non-
cirrhotic and cirrhotic liver patients. this difference in HRQol might be explained 
by the difference in acquired social support. social support is considered as one of 
the essentials of the transplant program as it influences post-transplant survival and 
HRQol 14-17. in other chronic liver patients, social support may be less regarded as 
an essential part of treatment. furthermore, the high HRQol level in transplanted 
patients may have been biased by selection of emotionally stable patients associated 
with the selection of transplantation candidates 17-19. 
our study confirmed earlier findings that the HRQol of transplanted patients 
does not equal the HRQol of healthy controls 20,21. after the initial sense of rebirth, 
the patients’ perception of good health may be affected by fear of becoming ill 
again, medical complications and psychological problems of accepting their new 
bodily integrity 22. nonetheless, other studies associated increasing time since 
transplantation with improvement of HRQol, although selection of survivors may 
have biased these findings 1,23. 
impact of hemochromatosis
Hemochromatosis patients revealed unexpected results with respect to pain and 
a deteriorating role emotional functioning with increasing age. in twenty to fifty 
percent of the hemochromatosis patients older than 50 years of age, an irreversible 
arthritis develops in finger joints that often progresses to other joints 24-27. Pain caused 
by arthritis, may have played a part in the worsening emotional functioning with 
increasing age. our data showed a significant positive relation between bodily pain 
and role emotional functioning in hemochromatosis patients. 
impact of viral hepatitis C
we showed that hepatitis C patients without interferon therapy revealed an impaired 
emotional functioning and mental health compared to other liver patients and non-
liver patients. interferon therapy significantly aggravated these abnormalities. these 
findings are supported by earlier reports 28-32. However, the emotional functioning 
and mental health in both hepatitis C groups might be confounded by a chronic 
condition predating the onset of viral infection and the use of interferon 31. a recent 
study reported that almost 50% of the hepatitis C patients used anti-depressant in the 
pre-diagnostic period, against 38.4% in controls (p < 0.001) 33. Moreover, depressive 
symptoms have been associated with intravenous drug use, whereas intravenous 
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drug use has been associated with hepatitis C infection. therefore, intravenous drug 
use could confound the mental health in hepatitis C patients 6,34. in our study we did 
not investigate the intravenous drug history of patients. 
other factors that may have influenced the role emotional functioning and mental 
health of hepatitis C patients are the diagnosis of the hepatitis C associated liver 
disease, feelings of stigmatisation or biological mechanisms. Hepatitis C infected 
individuals are relatively young and may suffer from concerns about their insecure 
and potentially fatal prognosis 35. Hepatitis C awareness campaigns may support 
or strengthen these concerns, though around 80% of all chronic hepatitis C patients 
will never develop cirrhosis and 95% will never develop hepatocellular carcinoma 24. 
furthermore, a hepatitis C status could have a disruptive effect on social networks 
due societal fears of virus transmission and the association of the disease with 
intravenous drug use 36,37. these feelings of stigmatisation are significantly associated 
with depression, anxiety and worsened quality of life 38. finally, the impaired mental 
health could be due to virus induced altered brain metabolism leading to cognitive 
impairments that affect daily performance and may indirectly lead to depression and 
anxiety. Hepatitis B patients demonstrated less signs of altered cerebral metabolism 
than hepatitis C patients 39-43.
interaction between physical and emotional/mental elements of HRQol
while seeking an explanation for HRQol findings in patients groups, we should not 
exclude the potential interaction between physical and emotional/mental elements 
of HRQol. according to the disability hypothesis, negative feelings like depression and 
fear could follow from the adverse consequences of accumulating health problems. in 
hemochromatosis patients, this hypothesis could support that an important disease-
specific factor such as progressive pain may have played a part in the worsening role 
emotional functioning with increasing age. in contrast, the psychosomatic hypothesis, 
which hypothesizes that severe negative feelings could cause or worsen physical 
health problems, points at the possible consequences of impaired emotional and 
mental health as found in hepatitis C patients 44-46.
implications
our findings underline the importance of multidimensional liver disease 
management. during consultations, besides attention for physical impairments of 
chronic liver patients, more attention is needed for psychological impairment and the 
potential interrelations between these two dimensions. Psychological interventions 
could lead to reduction in psychological morbidity as well as physical morbidity 47. 
therefore, psychological guidance of vulnerable groups like hemochromatosis and 
hepatitis C patients should be considered. Randomised clinical trials evaluating the 
effect of psychological interventions on physical and psychological impairments 
should be the next step for improvement of liver disease management.
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t his thesis describes the differences in Health Related Quality of life (HRQol) between liver patient subgroups, originating from a general population of 
chronic liver patients. furthermore, this thesis describes the construct validity of the 
liver disease symptom index 2.0 (ldsi), a disease-specific questionnaire. the results 
are based on data obtained in a cross-sectional study conducted by the department 
of gastroenterology and Hepatology and the department of epidemiology and 
Biostatistics of the erasmus Medical Center Rotterdam in collaboration with the 
dutch liver patient association (nederlandse leverpatiënten vereniging (nlv)) and 
the department of Medical Psychology and Psychotherapy of the erasmus Medical 
Center Rotterdam. this study was supported by the dutch digestive diseases 
foundation.
aiMs
the first aim of this study was to investigate the impact of disease stage (non-cirrhosis, 
compensated cirrhosis and decompensated cirrhosis), liver transplantation, aetiology 
(viral hepatitis, autoimmune hepatitis, cholestatic diseases, hemochromatosis and 
other liver diseases) and more specifically the impact of viral hepatitis B and C on the 
HRQol of chronic liver patients. 
our second aim was to evaluate the construct validity of the ldsi. the construct 
validity assesses the degree in which the ldsi measured what it was supposed to 
measure. we evaluated if expected relations between ldsi items and specific scales 
of the short form-36 (sf-36) or Multidimensional fatigue index-20 (Mfi-20) could be 
confirmed. furthermore, we investigated if specific ldsi items (the ldsi included 9 
items concerning severity of specific symptoms and 9 items concerning the hindrance 
of these specific symptoms in daily activities) could be considered as redundant. 
MetHods
in total 2020 members of the nlv received once a questionnaire by mail. the 
questionnaire included the (dutch) generic sf-36 version 1.2, the disease-specific 
ldsi, the domain-specific Mfi-20 and a background questionnaire for the collection 
of demographic and clinical information. of all members approached, 1617 members 
returned the questionnaires. in total 1243 respondents had a (history of ) liver disease. 
according to the regulations of the ethics Committee of the erasmus Medical 
Center Rotterdam, we excluded 21 respondents who did not give informed consent. 
furthermore, we excluded forty-seven respondents younger than 18 years of age. in 
total 1175 respondents were included in the analysis.
110
Chapter 7
Results
validity of the liver disease symptom index 2.0 (chapter 2)
in a pilot study conducted at the outpatient clinic of our department of 
gastroenterology and Hepatology, we pointed out that the ldsi 2.0 had an adequate 
feasibility and reliability. with respect to the construct validity evaluated in the study 
described in this thesis, we found that specific ldsi items mostly showed expected 
moderate correlations with specific sf-36 or Mfi-20 scales. the moderateness of 
these correlations additionally indicated that the ldsi provided HRQol information 
complementary to the HRQol information provided by the sf-36 and the Mfi-20. 
within the ldsi, some symptom severity items showed a high correlation with 
their accompanying symptom hindrance item, suggesting that one item of this pair 
was redundant. to investigate this, we estimated of each symptom severity item and 
each symptom hindrance item the impact on a poor generic HRQol, measured by the 
sf-36. we found that symptom hindrance items related differently to generic HRQol 
of patients than symptom severity items. this indicated that symptom severity items 
and symptom hindrance items measured other aspects of HRQol. therefore, we 
concluded that it is psychometrically sound to include both symptom severity items 
and symptom hindrance items into the ldsi 2.0.
impact of disease stage and liver transplantation on HRQol (chapter3)
we evaluated the impact of liver transplantation and disease stage on the generic 
and disease-specific HRQol and fatigue of chronic liver patients, corrected for 
among others gender, age and aetiology. the HRQol of transplanted liver patients 
sometimes approached the HRQol level of healthy controls but was mostly 
significantly impaired. nevertheless, the generic and disease-specific HRQol 
of transplanted patients was significantly less affected than in non-cirrhotic and 
cirrhotic liver patients. non-cirrhotic and compensated cirrhotic patients both 
revealed a significantly impaired HRQol compared to healthy controls, although 
we found few significant HRQol differences between these two groups. in contrast, 
decompensated cirrhotic patients showed a significantly worse disease-specific and 
generic HRQol and fatigue than non-cirrhotic and compensated cirrhotic patients, 
transplanted patients and healthy controls. a subgroup of reversed decompensated 
cirrhotic patients, fitted with respect to their generic and disease-specific HRQol and 
fatigue better in the compensated cirrhotic group than in the decompensated cirrhotic 
group.
impact of aetiology on HRQol (chapter 4)
we investigated the impact of aetiology on generic and disease-specific HRQol and 
fatigue of chronic liver patients, corrected for among others gender, age and disease 
stage. 
Prominent differences between aetiological groups were especially found in 
comparisons with viral hepatitis and hemochromatosis patients. Hemochromatosis 
patients experienced significantly more joint pain than other aetiological groups, 
whereas their role emotional functioning (limitations in daily activities due to 
emotional problems) worsened significantly with increasing age. viral hepatitis 
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patients showed significantly more limitations due to emotional problems and 
significantly worse mental health than other aetiological groups. in the ldsi, viral 
hepatitis patients revealed significantly higher odds ratios of severe worry about 
the family situation, severe depression and severe fear of complications than other 
aetiological groups. 
impact of viral hepatitis B and C on HRQol (chapter 5)
we evaluated the impact of viral hepatitis B and C on generic and disease-specific 
HRQol and fatigue of chronic liver patients, corrected for among others gender, age 
and disease stage. Hepatitis C patients showed a significantly worse physical-, social- 
and role emotional functioning, a significantly worse mental health, a more severe 
reduction in motivation and significantly higher odds ratios of severe depression 
and severe worry about the family situation than hepatitis B patients. when we 
categorised hepatitis C patients into groups with and without interferon therapy, 
hepatitis C patients without interferon therapy showed an impaired role emotional 
functioning and mental health compared to hepatitis B patients. interferon therapy 
significantly aggravated this impaired emotional functioning and mental health. 
Moreover, interferon led to additional impairments of other generic and disease-
specific HRQol dimensions and to significantly more fatigue. also compared to 
other chronic liver patients and patients with diabetes mellitus or cancer, both 
hepatitis C subgroups reported more limitations due to emotional problems and a 
worse mental health.
disCussion
integration of sub-study findings (chapter 6)
this study, conducted in a large non-clinical population approaching a population 
based study, confirms findings of earlier clinical studies in subgroups of liver disease. 
additionally, this study puts the impaired HRQol of liver patient subgroups in 
perspective. transplanted patients revealed a significantly better HRQol than non-
cirrhotic and cirrhotic liver patients, while decompensated cirrhotic patients showed 
the worst HRQol. Hemochromatosis patients reported significantly more pain than 
other aetiological groups and a progressive impairment of role emotional functioning 
with increasing age. in hepatitis C patients, role emotional functioning and mental 
health proved to be important contributors of impaired HRQol, especially in 
hepatitis C patients with interferon therapy. 
selection, disease-specific factors or environmental factors could explain these 
findings. the high HRQol level in transplanted patients may have been biased 
by selection of emotionally stable patients associated with the stringent selection 
of transplantation candidates. in hemochromatosis patients, an important disease 
specific factor such as pain may have played a part in the worsening emotional 
functioning with increasing age; depression or fear could follow from adverse 
consequences of accumulating health problems (disability hypothesis), while 
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the dose-response relationship between pain and quality of life may have led to 
increasing emotional distress in these patients.
with respect to the impaired role emotional functioning and mental health in 
hepatitis C patients, the explanatory value of selection as well as disease-specific or 
environmental factors should be considered. the real relationship between mental 
health and hepatitis C could be obscured by selection of patients with psychiatric 
morbidity prior to the hepatitis C diagnosis. additionally, history of intravenous 
drug use could be an important confounder as this factor might be related to 
psychiatric morbidity, independent of the hepatitis C infection. finally, the hepatitis 
C diagnosis its self, experienced limitations due to the hepatitis C infection such as 
impaired concentration, feelings of social stigma and fear for future complications of 
the disease may have played a part in the impaired emotional functioning and mental 
health of this patient group. 
our findings underline the importance of multidimensional liver disease 
management in chronic liver patients. during consultations, besides attention 
for physical impairments of chronic liver patients attention should be given to 
psychological impairment and the potential interrelations between these two 
dimensions. 
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d it proefschrift beschrijft de verschillen in gezondheid gerelateerde kwaliteit van leven (HRQol) tussen verschillende groepen leverpatiënten afkomstig van een 
algemene leverpatiënten populatie. daarnaast beschrijft dit proefschrift de construct 
validiteit van de liver disease symptom index 2.0 (ldsi), een ziekte-specifieke 
vragenlijst. 
de resultaten zijn gebaseerd op een cross-sectioneel onderzoek uitgevoerd 
door de afdeling Maag- darm- leverziekten en de afdeling epidemiologie en 
Biostatistiek van het erasmus Medisch Centrum Rotterdam in samenwerking met de 
nederlandse leverpatiënten vereniging (nlv) en de afdeling Medische Psychologie 
en Psychotherapie van het erasmus Medisch Centrum Rotterdam. Het onderzoek 
werd financieel gesteund door de Maag lever darm stichting.
doelstellingen
Het eerste doel van dit onderzoek was het evalueren van de invloed van ziekte 
stadium (niet-cirrose, gecompenseerde cirrose en gedecompenseerde cirrose), 
levertransplantatie, etiologie (virale hepatitis, autoimmuun hepatitis, cholestatische 
leverziekten, hemochromatose en overige leverziekten) en meer specifiek de invloed 
van virale hepatitis B en C op de HRQol van chronische leverpatiënten. Het tweede 
doel was de evaluatie van de construct validiteit van de ldsi. de construct validiteit 
beoordeelt in hoeverre de ldsi meet wat het zou moeten meten. we evalueerden 
of verwachte relaties tussen ldsi items en specifieke schalen van de short form-36 
(sf-36) en de Multidimensionele vermoeidheids index-20 (Mvi-20) konden worden 
bevestigd. daarnaast werd onderzocht of specifieke ldsi items (de ldsi bestaat uit 
9 items betreffende de ernst van specifieke symptomen en 9 items betreffende de 
hinder van deze specifieke symptomen tijdens dagelijkse activiteiten) als overbodig 
konden worden beschouwd. 
MetHoden
in totaal 2020 leden van de nlv ontvingen eenmalig een vragenlijst via de post.
de vragenlijst bestond uit de (nederlandse) generieke sf-36 versie 1.2, de ziekte-
specifieke ldsi, de domein-specifieke Mvi-20 en een achtergrond vragenlijst voor 
de verzameling van demografische en klinische gegevens. van alle benaderde leden, 
retourneerden 1617 leden de vragenlijst, waarvan 1243 respondenten een leverziekte 
of een leverziekte geschiedenis hadden. in overeenstemming met de afspraken 
gemaakt met ethische Commissie van het erasmus Medisch Centrum Rotterdam, 
excludeerden wij 21 respondenten die geen informed consent hadden gegeven. 
Bovendien excludeerden we 47 respondenten die jonger waren dan 18 jaar. in totaal 
namen 1175 respondenten deel aan de analyse.
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Resultaten
validiteit van de liver disease symptom index 2.0 (hoofdstuk 2)
in een pilot onderzoek, uitgevoerd op de polikliniek van de afdeling Maag- darm- 
leverziekten toonden wij aan dat de ldsi een adequate uitvoerbaarheid en 
betrouwbaarheid heeft. Met betrekking tot de construct validiteit geëvalueerd in 
het onderzoek beschreven in dit proefschrift, vonden wij dat specifieke ldsi items 
verwachte correlaties met specifieke sf-36 of Mvi-20 schalen vertoonden. Het feit 
dat deze correlaties laag tot gematigd waren gaf aan dat de ldsi HRQol informatie 
oplevert welk complementair is aan de HRQol informatie geleverd door de sf-36 en 
de Mfi-20. 
Binnen de ldsi vertoonden sommige ‘ernst van symptoom’-items hoge correlaties 
met het bijbehorende ‘hinder van symptoom’-item, hetgeen suggereerde dat één 
van de twee items van het item-paar overbodig was. om dit nader te onderzoeken, 
schatten we van elk ‘ernst van symptoom’-item en elk ‘hinder van symptoom’-item 
zijn effect op slechte generieke HRQol, gemeten met de sf-36. we vonden dat de 
relatie tussen ‘hinder van symptoom’-items en slechte generieke HRQol anders 
was dan de relatie tussen ‘ernst van symptoom’-items en slechte generieke HRQol. 
dit gaf aan dat ‘ernst van symptoom’-items en ‘hinder van symptoom’-items 
andere aspecten van HRQol meetten. Met deze reden concludeerden wij dat het 
psychometrisch verantwoord is om zowel ‘ernst van symptoom’-items als ‘hinder 
van symptoom’-items in de ldsi 2.0 te includeren.
effect van ziekte stadium en levertransplantatie op HRQol (hoofdstuk 3)
we evalueerden het effect van ziekte stadium en levertransplantatie op de generieke 
en ziekte-specifieke HRQol en vermoeidheid van chronische leverpatiënten, 
gecorrigeerd voor onder andere geslacht, leeftijd en etiologie. 
de HRQol van getransplanteerde patiënten benaderde soms het HRQol niveau 
van gezonde controles, maar was meestal significant verminderd. desalniettemin 
was de generieke en ziekte-specifieke HRQol van getransplanteerde patiënten 
significant minder verstoord dan in patiënten met en zonder cirrose. Patiënten zonder 
cirrose en patiënten met gecompenseerde cirrose vertoonden beiden een significant 
verminderde HRQol in vergelijking met gezonde controles. onderling vertoonden 
deze twee subgroepen nauwelijks significante HRQol verschillen. gedecompenseerde 
cirrose patiënten vertoonden een significant slechtere generieke en ziekte-specifieke 
HRQol en een ernstigere vermoeidheid dan patiënten zonder cirrose, patiënten met 
gecompenseerde cirrose, getransplanteerden en gezonde controles. een subgroep 
van patiënten die ooit gedecompenseerde cirrose hadden, maar onder invloed van 
medicatie en/of chirurgische interventies weer gerecompenseerd waren, lieten zien 
dat hun HRQol (generiek en ziekte-specifiek) en vermoeidheid meer overeenkomst 
vertoond met de HRQol en vermoeidheid van gecompenseerde cirrose patiënten 
dan met de HRQol en vermoeidheid van gedecompenseerde cirrose patiënten.
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effect van etiologie op HRQol (hoofdstuk 4) 
we onderzochten het effect van etiologie op de generieke en ziekte-specifieke HRQol 
en vermoeidheid van chronische leverpatiënten, gecorrigeerd voor onder andere, 
geslacht, leeftijd en ziekte stadium. 
Prominente verschillen tussen etiologieën werden met name gevonden wanneer 
wij etiologieën vergeleken met hemochromatose en virale hepatitis patiënten. 
Hemochromatose patiënten ervoeren significant meer gewrichtspijn dan andere 
etiologieën. daarnaast nam in hemochromatose patiënten het rol emotioneel 
functioneren (de mate van beperkingen tijdens het dagelijks functioneren ten gevolge 
van emotionele problemen) met een toenemende leeftijd signficant sterker af dan in 
andere etiologieën. virale hepatitis patiënten vertoonden een significant slechter rol 
emotioneel functioneren en een slechtere mentale gezondheid dan andere etiologieën. 
in de ldsi, toonden deze patiënten met virale hepatitis significant hogere odd ratio’s 
voor ernstige zorgen over de thuis/familie stiuatie, ernstige depressie en ernstige 
angst voor complicaties dan andere etiologieën.
effect van hepatitis B en C op HRQol (hoofdstuk 5)
we evalueerden het effect van hepatitis B en C op de generieke en ziekte-specifieke 
HRQol en vermoeidheid van chronische leverpatiënten, gecorrigeerd voor onder 
andere, geslacht, leeftijd en ziekte stadium. 
Hepatitis C patiënten hadden een significant slechter fysiek-, sociaal- en rol 
emotioneel functioneren, een slechtere mentale gezondheid, een ernstigere reductie 
van de motivatie en significant hogere odd ratio’s voor ernstige depressie en ernstige 
zorgen over de thuis/familie situatie in vergelijking met hepatitis B patiënten. 
na de verdeling van hepatitis C patiënten in een groep met en zonder interferon 
therapie, toonden hepatitis C patiënten zonder interferon therapie een significant 
slechter rol emotioneel functioneren en mentale gezondheid dan hepatitis B patiënten. 
Het rol emotioneel functioneren en de mentale gezondheid verslechterde nog eens 
in geval van gebruik van interferon therapie. daarnaast leidde interferon therapie 
tot additionele verstoringen in andere aspecten van generieke en ziekte-specifieke 
HRQol en tot signifcant meer vermoeidheid. ook in vergelijking met patiënten met 
diabetes mellitus en kanker, vertoonden beide hepatitis C subgroepen significant 
meer beperkingen door emotionele problemen (rol emotioneel functioneren) en een 
slechtere mentale gezondheid. 
disCussie
integratie van bevindingen (hoofdstuk 6)
dit onderzoek uitgevoerd in een grote niet-klinische populatie, bevestigt bevindingen 
van eerdere klinisiche onderzoeken verricht in verschillende groepen leverpatiënten. 
dit onderzoek plaatst bovendien de verminderde HRQol van de verschillende 
groepen leverpatiënten in perspectief. 
getransplanteerde leverpatiënten hadden een significant betere HRQol dan 
leverpatiënten zonder cirrose en met cirrose, terwijl gedecompenseerde cirrose 
patiënten de slechtste HRQol vertoonden. Hemochromatose patiënten rapporteerden 
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significant meer pijn dan andere etiologieën en een progressieve vemindering van 
het rol emotioneel functioneren met een toenemende leeftijd. in hepatitis C patiënten 
bleken rol emotioneel functioneren en mentale gezondheid een belangrijke bijdrage 
te leveren aan de verminderde HRQol in deze patiënten, met name in hepatitis C 
patiënten met interferon therapie.
selectie, ziekte-specifieke factoren en omgevingsfactoren zouden deze 
bevindingen kunnen verklaren. de goede HRQol in getransplanteerde patiënten kan 
gebiased zijn door een selectie van emotioneel stabiele patiënten welke geassocieerd 
is met de strenge selectie van levertransplantatie kandidaten. in hemochromatose 
patiënten, kan een ziekte-specifieke factor zoals pijn een rol hebben gespeeld in 
het verslechterende rol emotioneel functioneren met het toenemen van de leeftijd; 
depressie en angst kunnen voortkomen uit de negatieve gevolgen van toenemende 
gezondheidsproblemen (disability hypothese), terwijl de dosis-respons relatie tussen 
pijn en kwaliteit van leven zou kunnen leiden tot toenemende emotionele stress bij 
deze patiënten.
Met betrekking tot de verklaring van het verminderd rol emotioneel functioneren 
en de verminderde mentale gezondheid in hepatitis C patiënten dienen zowel 
selectie als ziekte-specifieke als omgevingsfactoren overwogen te worden. de 
werkelijke relatie tussen emotionele/mentale gezondheid en hepatitis C kan 
vertekend zijn door selectie van patiënten met een psychiatrische morbiditeit welke 
reeds aanwezig was voor de diagnose van hepatitis C. Bovendien kan intraveneus 
drugs gebruik een belangrijke confounder zijn, aangezien intraveneus drugs gebruik 
geassocieerd kan zijn met psychiatrische morbiditeit onafhankelijk van de hepatitis 
C infectie. tenslotte kunnen de hepatitis C diagnose zelf, ervaren beperkingen door 
de hepatitis C infectie zoals verminderde concentratie, gevoelens van sociaal stigma 
en angst voor toekomstige complicaties van de ziekte een rol hebben gespeeld in het 
verminderd rol emotioneel functioneren en de verminderde mentale gezondheid van 
deze groep.
onze bevindingen onderstrepen het belang van een multi-dimensioneel 
leverziekte management. tijdens consulten moet naast aandacht voor fysieke 
klachten van chronische leverpatiënten ook aandacht zijn voor psychologische 
klachten en de mogelijke relaties tussen deze twee dimensies.
appendices
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aPPendiX 1: liveR disease syMPtoM indeX 2.0
vult u de onderstaande vragen in, als u op dit moment een leverziekte heeft of als u 
ooit een leverziekte heeft gehad.
Met behulp van de onderstaande vragen willen wij een indruk krijgen in welke mate 
u de afgelopen week bepaalde klachten had en in welke mate u hinder had van deze 
klachten. Zet een kruisje bij het antwoord dat het best bij uw situatie past.
Bijvoorbeeld: 
wanneer u vindt dat u de afgelopen week geen jeuk had, dan plaatst u bij vraag 1a 
een kruisje in het meest linkse hokje. Hoe meer jeuk u had de afgelopen week, hoe 
meer u het kruisje in de richting van “in hoge mate” kunt plaatsen. 
slaat u alstublieft geen vragen over en plaats telkens één kruisje bij elke vraag. 
1a. in welke mate had u, de afgelopen week, jeuk?
in het geheel niet       in hoge mate
1B. in welke mate werd u, de afgelopen week, door jeuk gehinderd in uw werk of 
in uw dagelijkse bezigheden?
in het geheel niet        in hoge mate
1C. in welke mate werd u, de afgelopen week, door jeuk gehinderd in uw slaap?
in het geheel niet        in hoge mate
2a. in welke mate had u, de afgelopen week, gewrichtspijnen?
in het geheel niet        in hoge mate
2B. in welke mate werd u, de afgelopen week, door gewrichtspijnen gehinderd in 
uw werk of in uw dagelijkse bezigheden? 
in het geheel niet        in hoge mate
3a. in welke mate had u, de afgelopen week, pijn in de rechter bovenbuik?
in het geheel niet        in hoge mate
3B. in welke mate werd u, de afgelopen week, door pijn in de rechter bovenbuik 
gehinderd in uw werk of in uw dagelijkse bezigheden? 
in het geheel niet        in hoge mate
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4a. in welke mate was u, de afgelopen week, slaperig overdag?
in het geheel niet        in hoge mate
4B. in welke mate werd u, de afgelopen week, gehinderd door slaperigheid overdag 
in uw werk of in uw dagelijkse bezigheden?
in het geheel niet        in hoge mate
5a. in welke mate heeft u zich, de afgelopen week, zorgen gemaakt over de 
invloed van uw leverziekte op de thuis/gezinssituatie?
in het geheel niet        in hoge mate
5B. Hebben zorgen over de invloed van uw leverziekte op de thuis/gezinssituatie 
u, de afgelopen week, gehinderd in uw werk of in uw dagelijkse bezigheden?
in het geheel niet        in hoge mate
6a. in welke mate had u, de afgelopen week, een verminderde eetlust?
in het geheel niet        in hoge mate
6B. in welke mate werd u, de afgelopen week, door verminderde eetlust gehinderd?
in het geheel niet        in hoge mate
7a. in welke mate heeft u zich, de afgelopen week, door uw ziekte neerslachtig 
gevoeld?
in het geheel niet        in hoge mate
7B. in welke mate werd u, de afgelopen week, door neerslachtigheid ten gevolge 
van uw ziekte, gehinderd in uw werk, uw dagelijkse bezigheden en/of in uw 
contacten met andere mensen?
in het geheel niet        in hoge mate
8. in welke mate was u, de afgelopen week, bang voor mogelijke complicaties 
van uw leverziekte?
in het geheel niet        in hoge mate
9a. in welke mate was uw huid, de afgelopen week ten gevolge van uw leverziekte 
geel gekleurd?
in het geheel niet        in hoge mate
9B.  in welke mate hinderde een gele kleur van uw huid u, de afgelopen week, in 
uw werk, uw dagelijkse bezigheden en/of contacten met andere mensen?
in het geheel niet        in hoge mate
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aPPendiX 2: eXtRa nlv iteMs
de volgende vragen gaan over uw kwaliteit van leven sinds u een leverziekte hebt 
en hebben niet meer specifiek betrekking op uw kwaliteit van leven gedurende de 
afgelopen week. 
10. sinds ik een leverziekte heb, heb ik moeite om dingen te herinneren. 
Bijvoorbeeld: dingen die pas gebeurd zijn, waar ik dingen heb gelaten, 
afspraken die ik heb gemaakt.
in het geheel niet        in hoge mate
11. door mijn leverziekte ben ik een andere persoon dan ik vóór mijn leverziekte 
was.
in het geheel niet        in hoge mate
12. Mijn leverziekte belemmert mij bij financiële zaken. Bijvoorbeeld bij het 
afsluiten van een verzekering of een hypotheek.
in het geheel niet        in hoge mate
13. Mijn leverziekte dwingt mij om mijn tijd anders in te delen, dan ik zou willen.
in het geheel niet        in hoge mate
14. Mijn seksuele belangstelling is verminderd sinds ik weet dat ik een leverziekte 
heb.
in het geheel niet        in hoge mate
15. Mijn seksuele activiteit is verminderd sinds ik weet dat ik een leverziekte 
heb.
in het geheel niet       in hoge mate
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aPPendiX 3: sf-36 geZondHeidstoestand vRagenliJst 
(iQola sf-36 dutCH, veRsion 1.2)
 
Copyright © 1992 Health assessment lab.
all rights reserved 
instructie: deze vragenlijst gaat over uw standpunt t.a.v. uw gezondheid. Met behulp 
van deze gegevens kan worden bijgehouden hoe u zich voelt en hoe goed u in staat 
bent uw gebruikelijke bezigheden uit te voeren.
Beantwoord elke vraag door het antwoord op de aangegeven wijze te markeren. 
als u niet zeker weet hoe u een vraag moet beantwoorden, geef dan het best 
mogelijke antwoord.
1. Hoe zou u over het algemeen uw gezondheid beoordelen? 
uitstekend     1
Zeer goed     2
goed     3
Matig      4
slecht     5
2. Hoe beoordeelt u nu uw gezondheid over het algemeen, vergeleken met een 
jaar geleden? 
veel beter nu dan een jaar geleden  1
wat beter nu dan een jaar geleden  2
ongeveer hetzelfde nu als een jaar geleden 3
wat slechter nu dan een jaar geleden  4
veel slechter nu dan een jaar geleden  5
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3. de volgende vragen gaan over dagelijkse bezigheden die u misschien doet op 
een doorsnee dag. wordt u door uw gezondheid op dit moment beperkt bij 
deze bezigheden? Zo ja, in welke mate? (omcirkel één cijfer op elke regel)
BeZigHeden Ja, ernstig 
beperkt
 Ja, een beetje 
beperkt
nee, 
helemaal niet 
beperkt
a. forse inspanning, zoals hardlopen, 
tillen van zware voorwerpen, een 
veeleisende sport beoefenen
1 2 3
b. Matige inspanning, zoals een tafel 
verplaatsen, stofzuigen zwemmen of 
fietsen
1 2 3
c.  Boodschappen tillen of dragen 1 2 3
d. een paar trappen oplopen 1 2 3
e. eén trap oplopen 1 2 3
f.  Bukken, knielen of hurken 1 2 3
g. Meer dan een kilometer lopen 1 2 3
h. een paar honderd meter lopen 1 2 3
i.  ongeveer honderd meter lopen 1 2 3
j.  uzelf wassen of aankleden 1 2 3
4. Heeft u in de afgelopen 4 weken één van de volgende problemen bij uw werk 
of andere bezigheden gehad, ten gevolge van uw lichamelijke gezondheid? 
(omcirkel één cijfer op elke regel)
Ja nee
a. u besteedde minder tijd aan werk of andere bezigheden 1 2
b. u heeft minder bereikt dan u zou willen 1 2
c. u was beperkt in het soort werk of andere bezigheden 1 2
d. u had moeite om uw werk of andere bezigheden uit te voeren 
(het kostte u bijv. extra inspanning)
1 2
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5. Heeft u in de afgelopen 4 weken één van de volgende problemen bij uw werk 
of andere bezigheden gehad, ten gevolge van uw emotionele problemen (zoals 
depressieve of angstige gevoelens)? (omcirkel één cijfer op elke regel)
Ja nee
a. u besteedde minder tijd aan werk of andere bezigheden 1 2
b. u heeft minder bereikt dan u zou willen 1 2
c. u deed uw werk of andere bezigheden niet zo zorgvuldig als 
gewoonlijk
1 2
6. in hoeverrre hebben uw lichamelijke gezondheid of emotionele problemen u 
gedurende de afgelopen 4 weken gehinderd in uw normale omgang met familie, 
vrienden buren of bij activiteiten in groepsverband? 
Helemaal niet 1
enigzins   2
nogal    3
veel   4
Heel erg veel   5
7. Hoeveel lichamelijke pijn heeft u de afgelopen 4 weken gehad? 
geen    1
Heel licht    2
licht    3
nogal    4
ernstig    5
Heel ernstig   6
8. in welke mate bent u de afgelopen 4 weken door pijn gehinderd in uw normale 
werk (zowel werk buitenshuis als huishoudelijk werk)? 
Helemaal niet   1
een klein beetje   2
nogal    3
veel     4
Heel erg veel   5
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9.  deze vragen gaan over hoe u zich voelt en hoe het met u ging in de afgelopen 
4 weken. wilt u a.u.b. bij elke vraag het antwoord geven dat het beste benadert 
hoe u zich voelde. Hoe vaak gedurende de afgelopen 4 weken:
 (omcirkel één cijfer op elke regel)
altijd Meestal vaak soms Zelden nooit
a. voelde u zich levenslustig? 1 2 3 4 5 6
b. was u erg zenuwachtig? 1 2 3 4 5 6
c. Zat u zo in de put dat niets 
u kon opvrolijken?
1 2 3 4 5 6
d. voelde u zich rustig en 
tevreden?
1 2 3 4 5 6
e. Had u veel energie? 1 2 3 4 5 6
f. voelde u zich somber en 
neerslachtig?
1 2 3 4 5 6
g. voelde u zich uitgeput? 1 2 3 4 5 6
h. was u een gelukkig mens? 1 2 3 4 5 6
i. voelde u zich moe? 1 2 3 4 5 6
10. Hoe vaak hebben uw lichamelijke gezondheid of emotionele problemen u 
gedurende de afgelopen 4 weken gehinderd bij uw sociale actviteiten (zoals 
vrienden of familie bezoeken, etc)? 
altijd    1
Meestal    2
soms    3
Zelden    4
nooit    5
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11. Hoe Juist of onJuist is elk van de volgende uitspraken voor u? (omcirkel 
één cijfer op elke regel)
   
volkomen 
juist
grotendeels 
juist
weet ik 
niet
grotendeels 
onjuist
volkomen 
onjuist
a. ik lijk 
gemakkelijker 
ziek te worden 
dan andere 
mensen
1 2 3 4 5
b. ik ben even 
gezond als 
andere mensen 
die ik ken
1 2 3 4 5
c. ik verwacht dat 
mijn gezond-
heid achteruit 
zal gaan
1 2 3 4 5
d. Mijn 
gezondheid is 
uitstekend
1 2 3 4 5
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aPPendiX 4: MultidiMensionele veRMoeidHeids indeX-20
vult u de onderstaande vragen in als u op dit moment een leverziekte heeft of als u 
ooit een leverziekte heeft gehad.
Met behulp van de onderstaande uitspraken, willen wij een indruk krijgen van hoe u 
zich de laatste dagen voelt.
Bijvoorbeeld
wanneer u vindt dat de uitspraak voor u helemaal klopt, plaatst u dan een kruisje 
in het meest linkse hokje. Hoe minder u de uitspraak op uzelf van toepassing vindt, 
hoe meer u het kruisje naar rechts, richting ‘nee, dat klopt niet’, kunt plaatsen. slaat u 
alstublieft geen vragen over en plaats telkens één kruisje bij elke uitspraak.
Het gaat om hoe u zich de laatste dagen voelt.
1. ik voel me fit.
Ja, dat klopt      nee, dat klopt niet
2. lichamelijk voel ik me tot weinig in staat. 
Ja, dat klopt      nee, dat klopt niet
3. ik zit vol activiteit.
Ja, dat klopt      nee, dat klopt niet
4. ik heb zin om allerlei leuke dingen te gaan doen.
Ja, dat klopt      nee, dat klopt niet
5. ik voel me moe.
Ja, dat klopt      nee, dat klopt niet
6. ik vind dat ik veel doe op een dag.
Ja, dat klopt      nee, dat klopt niet
7. als ik ergens mee bezig ben, kan ik mijn gedachten er niet goed bijhouden.
Ja, dat klopt      nee, dat klopt niet
8. lichamelijk kan ik veel aan.
Ja, dat klopt      nee, dat klopt niet
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9. ik zie er tegen op om iets te doen.
Ja, dat klopt      nee, dat klopt niet
10. ik vind dat ik weinig doe op een dag.
Ja, dat klopt      nee, dat klopt niet
11. ik kan me goed concentreren.
Ja, dat klopt      nee, dat klopt niet
12. ik voel me uitgerust.
Ja, dat klopt      nee, dat klopt niet
13. Het kost me moeite ergens mijn aandacht bij te houden.
Ja, dat klopt      nee, dat klopt niet
14. lichamelijk voel ik me in een slechte conditie.
Ja, dat klopt      nee, dat klopt niet
15. ik zit vol plannen.
Ja, dat klopt      nee, dat klopt niet
16. ik ben gauw moe.
Ja, dat klopt      nee, dat klopt niet
17. er komt weinig uit mijn handen.
Ja, dat klopt      nee, dat klopt niet
18. de zin om dingen te ondernemen ontbreekt mij.
Ja, dat klopt      nee, dat klopt niet
19. Mijn gedachten dwalen gemakkelijk af.
Ja, dat klopt      nee, dat klopt niet
20. lichamelijk voel ik me in een uitstekende conditie.
Ja, dat klopt      nee, dat klopt niet
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aPPendiX 5: aCHteRgRond vRagenliJst
de volgende vragen gaan over uw persoonlijke situatie en uw leverziekte. Zet een 
kruisje bij het antwoord dat het best bij uw situatie past.
1. Bent u bereid om aan dit onderzoek mee te doen?
 Ja
 nee
ook als u niet wilt meedoen aan ons onderzoek, verzoeken wij u, om toch de 
vragenlijst naar ons terug te sturen door middel van de antwoordenvelop! u hoeft 
dan uiteraard de rest van de vragenlijst niet in te vullen.
2. Bent u:
 man
 vrouw
3. geboortejaar: 
Jaar……………..
4. wat is uw geboorteland?
 nederland
 nederlandse antillen
 suriname
 turkije
 Marokko
 anders, namelijk……………………………………………………….
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5. wat is uw hoogste volledig afgemaakte opleiding? 
 ik heb geen enkele opleiding volledig afgemaakt.
 lagere school
 lager beroepsonderwijs (huishoudschool, lts, leao)
 Middelbaar algemeen voortgezet onderwijs (Mavo, ivo, Mulo)
 Middelbare beroepsopleiding (Mts, Meao, MHno, inas)
  Hoger algemeen en voorbereidend wetenschappelijk onderwijs
 (Havo, vwo, HBs, MMs, gyMnasiuM, atHeneuM)
 Hoger beroepsonderwijs
 universiteit
6.  wat is uw burgerlijke status?
 getrouwd / samenwonend
 ongetrouwd / weduwe of weduwnaar / alleenstaand
7. geeft u een ruwe schatting van het aantal uur dat u, gemiddeld per week, 
besteedt aan betaald werk, vrijwilligerswerk, huishoudelijk werk en studie.
 indien u geen tijd besteedt aan het desbetreffende werk of studie, vult u dan 
een 0 in.
Betaald werk vrijwilligerswerk Huishoudelijk werk studie (zelfstudie 
en lessen)
8. geeft u een ruwe schatting van het aantal uur dat u, gemiddeld per week, 
besteedt aan de volgende vrije tijd-activiteiten? 
 indien u geen tijd besteedt aan de betreffende activiteiten-categorie, vult u dan 
een 0 in.
activiteiten zonder lichamelijke inspan-
ning. (Bijv. schaken, kaarten, puzzelen, 
breien, borduren, tv kijken.)
activiteiten met lichamelijke inspan-
ning. (Bijv. voetballen, fietsen, wande-
len, tuinieren.)
9. waarom bent u lid van de nederlandse leverpatiënten vereniging?
 ik heb zelf een leverziekte (gehad)
 ik ben betrokken bij een persoon die een leverziekte heeft (gehad)
 ik ben lid om een andere reden, namelijk 
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indien u zelf geen leverziekte heeft (gehad), dan hoeft u de resterende vragen niet te 
beantwoorden! wij verzoeken u de vragenlijst naar ons terug te sturen door middel 
van de antwoordenvelop!
indien u wel een leverziekte heeft of ooit een leverziekte heeft gehad, gaat u dan door 
naar vraag 10 en verder.
10. Heeft u op dit moment een leverziekte die reeds meer dan 6 maanden duurt?
 Ja
 nee
11.  graag willen wij van u weten welke leverziekte(n) u heeft (gehad).
  in de onderstaande lijst staan verschillende leverziekten in categorieën (dikgedrukt) 
vermeld. leest u de lijst eerst rustig door.
 wilt u in deze lijst met een kruisje aangeven welke van de volgende leverziekte(n) 
u heeft (gehad). er zijn meerdere antwoorden mogelijk! 
 indien uw leverziekte niet in de lijst wordt vermeld, vul dan onder aan de 
tabel uw leverziekte(n) in. geeft u vervolgens de maand en het jaar waarin de 
betreffende leverziekte bij u is vastgesteld en of de duur van de leverziekte wel 
of niet meer dan 6 maanden is.
 geeft u tenslotte aan of uw leverziekte wel of niet wordt onderdrukt met 
medicijnen en of de leverziekte wel of niet genezen is. 
 let oP: de lijst loopt door op de volgende pagina!
Code leverziekten Jaar waarin 
de leverziekte 
bij u werd 
vastgesteld?
duur van de 
leverziekte 
langer dan 6 
maanden?
Ja / nee
is de lever-
ziekte onder-
drukt met 
medicijnen?
Ja / nee
is de lever-
ziekte gen-
ezen?
Ja / nee
1.0 virale Hepatitis
1.01 Hepatitis a
1.02 Hepatitis B
1.03 Hepatitis C
1.04 Hepatitis d
1.05 Hepatitis e
1.06 Hepatitis g
1.07 Hepatitis CMv 
(Cytomegalo virus)
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1.08 Hepatitis eBv (epstein-
Barr virus)
2.0 Parenchymateuze 
leverziekten, niet viraal
2.01 autoimmuun hepatitis
2.02 alcohol hepatitis
2.03 geneesmiddelen hepatitis
2.04 toxische hepatitis
2.05 Hepatitis eCi (Hepatitis 
oorzaak onbekend)
2.06 steatose (leververvetting)
2.07 granulomateuze hepatitis
2.08 sarcoidose
2.09 Reye syndroom
3.0 vaatafwijkingen
3.01 Budd-Chiari syndroom
3.02 veneuze stuwing
3.03 veno-occlusive disease
3.04 Porta-thrombose
3.05 idiopatische (of primaire) 
portale hypertensie
3.06 Cardiale cirrose
4.0 Cholestatische 
leverziekten
4.01 Primaire Biliaire Cirrose 
(PBC)
4.02 Primaire scleroserende 
Cholangitis (PsC)
4.03 secundaire Billiaire Cirrose
5.0 Congenitale leverziek-
ten, metabool
5.01 Ziekte van wilson 
(koperstapelings-ziekte)
5.02 Haemochromatose
5.03 alpha -1-antitrypsine-
deficiëntie
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5.05 Porfyrie
5.06 syndroom van gilbert
5.07 syndroom van dubin-
Johnson
5.08 Ziekte van Crigler-najer
5.09 Primaire oxalose
5.10 syndroom van Rotor
5.11 galactosemie
5.12 Ziekte van niemann-Pick
5.13 Ziekte van gaucher 
(sfingolipidose)
6.0 Congenitale ziekten, 
anatomische afwijkingen
6.01 Congenitale levercysten
6.02 Choledochus-cyste(n)
6.03 Congenitale leverfibrose
6.04 galgang-atresie
6.05 syndroom van allagille
6.06 arterio-veneuze 
malformatie
6.07 M. osler-weber-Rendu
6.08 syndroom van Caroli
7.0 Haardvormige afwijkin-
gen, kwaadaardig
7.01 Hepatocellulair carcinoom
7.02 galgang carcinoom
7.03 aPudoma
7.04 Carcinoïd syndroom
7.05 levermetastasen
7.06 Cholangiocellulair 
carcinoom
8.0 Haardvormige afwij-
kingen, goedaardig
8.01 Hepatocellulair adenoom
8.02 Hemangioom
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8.03 focale nodulaire 
hyperplasie
8.04 nodulaire regeneratieve 
hyperplasie
9.0 Parasitaire leverziekten
9.01 amoeben abces
9.02 schistosomiasis
9.03 echinococcus-cyste(n)
10.0 Cholelithiasis
10.1 Cholecystolithiasis 
(galblaassteenziekte)
10.2 Choledocholithiasis 
(galgangsteenziekte)
10.3 intrahepatische galstenen
11.0 andere leverziekten
11.01 Hepatische 
encephalopathie
12.0 Mijn leverziekte(n) 
wordt/worden niet in 
de tabel vermeld. Mijn 
leverziekte(n) is/zijn:
12.01 1.
12.02 2.
12.03 3.
12. Heeft u een levertransplantatie ondergaan?
 Ja, namelijk op: dag………./maand………/jaar……….
 nee
13. Heeft u cirrose (sterke verlittekening van de lever met een hobbelig lever-
oppervlak)?
 Ja
 nee
14. Heeft u een vergrote milt (gehad)?
 Ja 
 nee
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15. Heeft u een ophoping van vocht in uw buik (ascites) (gehad)?
 Ja
 nee
16. Heeft u een bloeding uit spataderen in uw slokdarm (varices bloeding) (gehad)?
 Ja
 nee
17. Heeft u in het jaar 2000 nog een bloeding uit spataderen in uw slokdarm of een 
ophoping van vocht in uw buik gehad?
 Ja
 nee
18. Heeft u andere ernstige complicaties van een levercirrose (gehad)?
 Ja, namelijk:
 leverkanker (hepatocellulair carcinoom)
 (dreigend) levercoma (encephalopathie)
 overig, namelijk…………………………………………………
……………………….....................................…………………………
 nee
19. Heeft u nog andere ziekten/aandoeningen dan uw leverziekte(n), die u belem-
meren in het dagelijks functioneren? Meerdere antwoorden zijn mogelijk!
 Ja, namelijk ziekten of aandoeningen van:
 hart- en vaten (bijv. hoge bloeddruk) 
 het zenuwstelsel (bijv. ziekte van Parkinson)
 de luchtwegen (bijv. astma)
 de spieren 
 de gewrichten (bijv. reuma)
 de urinewegen
 het maag/darmstelsel (bijv ziekte van Crohn, Colitis ulcerosa) 
 suikerziekte
 het oog
 psychische aandoeningen
 overige, namelijk……………………………………….
 nee
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 20. Heeft u medicijnen in verband met psychische klachten?
 Ja
 nee
21. gebruikt u slaapmiddelen?
 Ja
 nee
22. graag willen wij van u weten welke medicijnen u op dit moment gebruikt. 
 in de onderstaande lijst worden een aantal medicijnen weergegeven.
 leest u de lijst eerst rustig door.
 kruist u de medicijn(en) aan die u op dit moment gebruikt. 
Medicijnen gebruik nu
1 interferon (intron a, Roferon) 
2 Peg-interferon 
3 lamivudine 
4 famciclovir 
5 entecavir 
6 Ribavirine 
7 amantadine 
8 Prednison 
9 tacrolimus (Prograft) 
10 Ciclosporine (neoral) 
11 ursodeoxycholzuur (ursochol, ursofalk) 
12 Budesonide 
13 furosemide (lasix) 
14 spironolactone (aldactone) 
15 Propanolol (inderal) 
16 antihypertensiva (tegen hoge bloeddruk) 
17 antidiabetica (tegen suikerziekte) 
139
18 Medicatie tegen luchtweg aandoeningen 
19 slaapmiddelen 
20 Middelen tegen psychische klachten (bijvoorbeeld: 
antidepressiva, middelen tegen angst, etc) 
21 overig, namelijk 
1
2
3
4
5
6
7
8
9
10

dankwoord
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